

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> C12N 15/12, 15/74, C07K 14/47, 16/18, C12N 9/12, 1/21, C12Q 1/68, G01N 33/50, 33/53, A61K 38/17, 39/00, 48/00		<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 97/48803</b> <b>(43) International Publication Date:</b> 24 December 1997 (24.12.97)
<b>(21) International Application Number:</b> PCT/US97/10598 <b>(22) International Filing Date:</b> 18 June 1997 (18.06.97) <b>(30) Priority Data:</b> 08/666,798 18 June 1996 (18.06.96) US <b>(60) Parent Application or Grant</b> <b>(63) Related by Continuation</b> US 08/666,798 (CIP) Filed on 18 June 1996 (18.06.96) <b>(71) Applicant (for all designated States except US):</b> INCYTE PHARMACEUTICALS, INC. [US/US]; 3174 Porter Drive, Palo Alto, CA 94304 (US). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> AU-YOUNG, Janice [US/US]; 1419 Kains Avenue, Berkeley, CA 94702 (US). HAWKINS, Phillip, R. [US/US]; 750 N. Shoreline Boul- vard #96, Mountain View, CA 94034 (US). HILLMAN, Jen- nifer, L. [US/US]; 230 Monroe Drive #12, Mountain View, CA 94034 (US).		<b>(74) Agent:</b> BILLINGS, Lucy, J.; Incyte Pharmaceuticals, Inc., 3174 Porter Drive, Palo Alto, CA 94304 (US).  <b>(81) Designated States:</b> AT, AU, BR, CA, CH, CN, DE, DK, ES, FI, GB, IL, JP, KR, MX, NO, NZ, RU, SE, SG, US, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	

**(54) Title:** HUMAN PROTEIN KINASE C INHIBITOR HOMOLOG

Contig: 75682



**(57) Abstract**

The present invention provides a polynucleotide (ipkc) which identifies and encodes a novel human protein kinase C inhibitor homolog (IPKC). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding IPKC. The invention also provides for the use of purified IPKC and its agonists in the commercial production of recombinant proteins and in pharmaceutical compositions for the treatment of diseases associated with the expression of IPKC. Additionally, the invention provides for the use of antisense molecules complementary to ipkc in pharmaceutical compositions for treatment of diseases associated with the expression of IPKC. The invention also describes diagnostic assays which utilize diagnostic compositions comprising the polynucleotide, fragments or the complement thereof, which hybridize with the genomic sequence or the transcript of ipkc. The present invention also relates to anti-IPKC antibodies which specifically bind to IPKC.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

## HUMAN PROTEIN KINASE C INHIBITOR HOMOLOG

### TECHNICAL FIELD

The present invention relates to nucleic acid and amino acid sequences of a novel human protein kinase C inhibitor homolog and to the use of these sequences in the diagnosis, study,

5 prevention and treatment of disease.

### BACKGROUND ART

Protein kinase C, PKC, is a family of widely distributed signal transduction proteins important for cell growth, differentiation, and other responses. PKC is activated by growth factors, hormones, and other external messengers via stimulation of phospholipase C and the  
10 generation of the second messengers, inositol triphosphate and diacylglycerol. All members of the PKC family share significant sequence homology and perform signal transduction via protein phosphorylation. Almost all cell types express one or more isoforms of PKC.

The activity of an endogenous inhibitor of PKC has been detected in bovine, avian, murine, and human tissues. The first complete primary structure of an endogenous inhibitor of  
15 protein kinase C, PKCI-1, was derived from bovine brain (Pearson, JD et al (1990) J Biol Chem 265:4583-4591). PKCI-1 has a specific site of interaction with PKC and inhibits the phosphorylation ability of PKC. In addition to the bovine sequence, a complete amino acid sequence of PKCI-1 has been deduced from the maize, rat, and human genes (Simpson GG et al (1994) Biochim Biophys Acta 1222: 306-308; Waller SJ and Murphy D (1994), unpublished;  
20 Brzoska PM et al (1995) PNAS USA 92: 7824-7828). The bovine PKCI-1 was shown to be a zinc (Zn) binding protein (Simpson et al, supra). The site of Zn binding has been localized to a 11 amino acid fragment (Mozier et al (1991) FEBS Lett 279:14-18), and the Zn binding domain is conserved among PKCI-1 molecules of other species.

### Disease and PKC

25 PKC activation plays a significant role in multidrug resistance (MDR), a major contributing factor in the failure of many chemotherapeutic cancer regimens (Grunicke H et al (1994) Ann Hematol 69:S1-6). PKC regulates proteins that act to make cancer cells drug resistant, such as FOS, Jun, glutathione S-transferase, deoxy-thymidine monophosphate synthase, metallothionein, and mdr-1-encoded P-glycoprotein. PKC leads to the increase in transcription  
30 of these genes through protein phosphorylation. PKC inhibitors or antagonists that interfere with the phosphorylation function of PKC have been shown to reduce the expression of genes that mediate MDR. Evidence suggests that the selective inhibition of a particular PKC, cPKC alpha,

might allow successful management of colon cancer with standard cytotoxic chemotherapeutic regimens (O'Brian CA et al (1995) *Prog Clin Biol Res* 391:117-120). Thus, PKC is a promising agent for cancer treatment.

In addition to contributing to MDR, PKC activation is often a critical event in tumor promotion (O'Brian CA and Ward NE (1989) *Cancer Metastasis Rev* 8:199-214). For example, PKC alpha phosphorylates and activates the growth promoting gene Raf-1 (Kolch W et al (1993) *Nature* 364:249-252). Without PKC induced Raf-1 activation, the ability to transform NIH3T3 cells is greatly inhibited. In cultured melanocytes loss of a particular PKC isotype has been implicated in cellular transformation (Yamanishi DT et al (1994) *Crit Rev Oncog* 5:429-450).

PKC participates in the sequence of molecular events that underlie learning and memory (Olds JL and Alkon DL (1991) *New Biol* 3:27-35). The cellular distribution of PKCs changes as a result of memory storage in cells that have been demonstrated to act in memory and learning (Saito N et al (1994) *Brain Res* 656:245-256). Thus, molecules that modulate PKC may modify the ability to learn and remember. PKC gamma mutant mice exhibit mild deficits in spatial and contextual learning, further implicating PKCs in learning and memory (Abeliovich A et al (1993) *Cell* 75:1263-1271). Memory deterioration is one of the main characteristics and earliest signs of Alzheimer's disease.

PKCs can act in several ways to stimulate apoptosis (programmed cell death) in various cell types. PKCs can block the activation of other calcium-dependent enzymes triggering apoptosis (Lucas M et al (1995) *Gen Pharmacol* 26:881-887). Activation of phosphatases by ceramide and inhibition of PKC by sphingosine mediates the sphingomyelin pathway to apoptosis. A putative PKC target, p34cdc2, can act to stimulate apoptosis when its activity is uncoupled from the completion of DNA replication. In addition, p21Ras mediates proliferative responses and also renders cells susceptible to apoptosis after inhibition of PKC activity (Chen CY et al (1996) *J Biol Chem* 271:2376-2379). The T lymphocytes of mice in which the Fas mediated apoptosis pathway has been knocked out rely on a PKC dependent apoptotic mechanism for selection against self-reactive T-cells (Ohkusu K et al (1995) *Eur J Immunol* 25: 3180-3186). Thus, PKC has a role in immune cell development. Saikosponin b2 induces apoptosis in B16 melanoma cells by down regulation of PKC activity (Zong et al (1996) *Biochem Biophys Res Commun* 219:480-485). Furthermore, proteolytic activation of PKC delta by an ICE-like protease stimulates apoptosis in human tumor cell line U-937 (Emoto Y et al (1995) *EMBO J* 14:6148-5156).

Many synthetic inhibitors of PKC have been reported, such as chlorpromazine (Mori T et al (1980) J Biol Chem 255:8378-8380), trifluoperazine (Schatzman RC et al (1981) Biophys Res Commun 98:669-676), tamoxifen (O'Brien CA et al (1985) Cancer Res 45:2462-2465), aminoacridines (Hannun YA et al (1988) J Biol Chem 263:5124-5131), isoquinolinesulfonamides (Hidaka H et al (1984) Biochemistry 23:5036-5141), and various synthetic peptides (House C and Kemp BE (1987) Science 238:1726-1728; Ward NE et al (1995) Cancer Lett 88:37-40). There is much evidence to suggest that PKC blockers may modify PKC activity in normal or disease cells. For example, PKC blockers have been shown to inhibit the growth of cancer cells both in vitro and in vivo (Levitzki A (1994) Eur J Biochem 226:1-13).

10 The PKC inhibitor bisindolylmaleimide GF109203X (bisi) can affect the neuroblastoma cell line Neuro-2A in one of two ways. Without serum, neurite outgrowth is potentiated by bisi, while with serum, apoptosis occurs (Behrens MM et al Cell Growth Differ (1995) 6:1375-1380). Other PKC inhibitors, including hypericin, staurosporine, tamoxifen, and the phorbol ester PMA induce apoptosis in the human neuroblastoma cell line SK-N-SH (Zhang W et al (1995) Cancer

15 Lett 96:31-35). PKC blockers may have utility beyond cancer indications. The PKC inhibitor H-7 induces apoptosis in Fas minus mouse T lymphocytes (Ohkusu et al (1995) Eur J Immunol 25: 3180-3186). It is possible that PKC inhibitors may help manage auto-immune diseases by inducing apoptosis in self-reactive T cells. However, synthetically made PKC inhibitors have often failed to advance in drug development because of a high level of toxicity and/or a low level

20 of specificity. The selective inhibition of PKC may allow successful management of diseases associated with PKC induced effects, such as cancer, memory disorders, and auto-immune diseases. Therefore the identification of novel PKC inhibitors provides opportunities for early treatment of diseases associated with PKC.

### DISCLOSURE OF THE INVENTION

25 The present invention relates to a novel human protein kinase C inhibitor homolog initially identified among the partial cDNAs from a THP-1 library (THP1PEB01) and to the use of the nucleic acid and amino acid sequences disclosed herein in the study, diagnosis, prevention and treatment of disease. Nucleic acid encoding a portion of the novel human protein kinase C inhibitor homolog was also found in cDNA libraries from stimulated macrophages, breast

30 tumors, and cells of the nervous system, including tumors.

Nucleic acid encoding a portion of the human protein kinase C inhibitor homolog of the present invention was first identified in the partial cDNA, Incyte Clone 75682 (SEQ ID NO:7),

through a computer-generated search for amino acid sequence alignments. Other partial cDNA sequences were identified and assembled to yield SEQ ID NO:1. The nucleic acid sequence, SEQ ID NO:1, disclosed herein and designated in lower case, *ipkc*, encodes the amino acid sequence, SEQ ID NO:2, designated in upper case, IPKC. The present invention is based, in part, on the chemical and structural homology between IPKC and the putative protein kinase C inhibitor (GI 493051; Waller and Murphy, *supra*). IPKC has 61% identity to the putative protein kinase C inhibitor. As illustrated by Figures 5 and 6, IPKC and GI 493051 have very similar hydrophobicity plots suggesting shared configuration and activity. The novel IPKC is 128 amino acids long and lacks obvious glycosylation sites.

10 The nucleic acid sequence, oligonucleotides, peptide nucleic acids (PNA), fragments, portions or antisense molecules thereof, may be used in diagnostic assays of body fluids or biopsied tissues to detect the expression level of *ipkc*. For example, *ipkc* sequences designed from (SEQ ID NO:1) can be used to detect the presence of the mRNA transcripts in a patient or to monitor modulation of the transcripts during treatment.

15 The present invention relates, in part, to the inclusion of the polynucleotide encoding IPKC in an expression vector which can be used to transform host cells or organisms. Such transgenic hosts are useful for the production of IPKC. Purified IPKC or fragments of IPKC may be useful as a pharmaceutical composition. For example, they may be used to delay or lessen the onset of Alzheimer's disease. Purified IPKC or fragments of IPKC may be useful as a  
20 pharmaceutical composition to inhibit or reverse the development of tumors

The *ipkc* nucleic acid sequence also provides for the design of antisense molecules useful in diminishing or eliminating expression of the genomic nucleotide sequence in melanomas or other cancers where IPKC activity may hinder a desired activity of PKC.

The invention further provides diagnostic assays and kits for the detection of naturally  
25 occurring IPKC. It provides for the use of purified IPKC as a positive control and to produce anti-IPKC antibodies which can be used to quantitate the amount of IPKC in human body fluids or biopsied tissues. IPKC can also be used to identify agonists which induce the production of or prolong the lifespan of the IPKC molecule in vivo or in vitro.

The invention comprises pharmaceutical compositions comprising IPKC, *ipkc* antisense  
30 molecules capable of disrupting expression of the genomic sequence, and agonists, antibodies, antagonists or inhibitors of the IPKC. These compositions are useful for the prevention or treatment of conditions associated with expression of IPKC or of PKC.

### BRIEF DESCRIPTION OF DRAWINGS

Figures 1A and 1B display the nucleic acid sequence (SEQ ID NO:1) and deduced amino acid sequence (SEQ ID NO:2) of the human protein kinase C inhibitor homolog. The alignment of the sequences was produced using MacDNAsis software (Hitachi Software Engineering Co Ltd). Figure 2 shows the diagram for the assembled ipkc sequence (SEQ ID NO:1) and 5 partial cDNAs, Incyte Clones 1004126, 488082, 899728, 625024, 75682 (SEQ ID NOs:3-7). SEQ ID NO:1 was assembled electronically using the GELVIEW™ fragment assembly program from GCG (Madison WI).

Figure 3 shows the northern analysis for Incyte Clone 75682 (SEQ ID NO:7). The northern analysis was produced electronically using LIFESEQ™ database (Incyte Pharmaceuticals, Palo Alto CA) and shows cDNA libraries in which ipkc was expressed.

Figure 4 shows the amino acid sequence alignments among IPKC (75682; SEQ ID NO: 2), rat putative protein kinase C inhibitor (GI 493051; SEQ ID NO:8), human PKCI-1 (GI 862933; SEQ ID NO:9), and bovine putative protein kinase C inhibitor (GI 493050; SEQ ID NO:10). Sequences were aligned using the multisequence alignment program of DNASTar software (DNASTar Inc, Madison WI).

Figure 5 shows the hydrophobicity plot for IPKC, SEQ ID NO:2. In Figures 5 and 6, the X axis reflects amino acid position, and the negative Y axis, hydrophobicity. The hydrophobicity plots were generated using MacDNAsis software.

Figure 6 shows the hydrophobicity plot for GI 493051, SEQ ID NO:8.

### MODES FOR CARRYING OUT THE INVENTION

The present invention relates to a novel human protein kinase C inhibitor initially identified among the partial cDNAs from a THP-1 library (THP1PEB01) and to the use of the nucleic acid and amino acid sequences in the study, diagnosis, prevention and treatment of disease.

Nucleic acid encoding a portion of the human putative protein kinase C inhibitor homolog of the present invention was first identified in the partial cDNA, Incyte Clone 75682 (SEQ ID NO:7), through a computer-generated search for amino acid sequence alignments. Other partial cDNA sequences were identified and assembled to yield SEQ ID NO:1. The ipkc nucleic acid sequence, SEQ ID NO:1, encodes the amino acid sequence, SEQ ID NO 2. The present invention is based, in part, on the chemical and structural homology among IPKC, the putative protein kinase C inhibitor homolog (GI 493051; Waller and Murphy, supra), and human PKCI-1

(GI 862933; Brzoska et al (1995) PNAS USA 92: 7824-7828). IPKC has 61% identity to rat and bovine putative protein kinase C inhibitor and 55% identity to human PKCI-1. IPKC, rat and bovine putative protein kinase C inhibitors, and human PKCI-1 have very similar hydrophobicity suggesting shared configuration and activity. The novel IPKC is 128 amino acids long and lacks  
5 obvious glycosylation sites.

As used herein, IPKC refers to the amino acid sequence of IPKC from any species, particularly mammalian, including bovine, ovine, porcine, murine, equine, and preferably human, in a naturally occurring form or from any source whether natural, synthetic, semi-synthetic or recombinant. As used herein, "naturally occurring" refers to an amino acid sequence which is  
10 found in nature.

The present invention also encompasses IPKC variants. A preferred IPKC variant is one having at least 80% amino acid sequence similarity, a more preferred IPKC variant is one having at least 90% amino acid sequence similarity and a most preferred IPKC variant is one having at least 95% amino acid sequence similarity to the IPKC amino acid sequence (SEQ ID NO:2).

15 The nucleic acid sequence, oligonucleotides, fragments, portions or antisense molecules thereof, may be used in diagnostic assays of body fluids or biopsied tissues to detect the expression level of ipkc. For example, ipkc sequences designed from the sequence (SEQ ID NO:1) or the sequences found in Incyte Clones 1004126, 488082, 899728, 625024, 75682 (SEQ ID NOs:3-7) can be used to detect the presence of the mRNA transcripts in a patient or to  
20 monitor the modulation of transcripts during treatment.

The present invention relates, in part, to the inclusion of the polynucleotide encoding IPKC in an expression vector which can be used to transform host cells or organisms. Such transgenic hosts are useful for the production of IPKC.

The nucleic acid sequence also provides for the design of antisense molecules useful in  
25 diminishing or eliminating expression of the genomic nucleotide sequence in tumor or cancer cells.

IPKC can also be used in screening assays to identify agonists which induce the production of or prolong the lifespan of the IPKC molecule in vivo or in vitro. IPKC can be similarly used to screen for antagonists or inhibitors which bind IPKC. Such antagonists or  
30 inhibitors can be delivered into the vascular system or appropriate cell compartments to interact with IPKC and alter protein folding.

The invention also relates to pharmaceutical compositions comprising IPKC, or fragments



thereof, ipkc antisense molecules capable of disrupting expression of the naturally occurring gene, and agonists, antibodies, antagonists or inhibitors of IKPC. These compositions are useful for the prevention or treatment of conditions associated with abnormal expression of PKC such as melanomas.

5        "Nucleic acid sequence" as used herein refers to an oligonucleotide, nucleotide or polynucleotide, and fragments or portions thereof, and to DNA or RNA of genomic or synthetic origin which may be single- or double-stranded, and represent the sense or antisense strand. Similarly, amino acid sequence as used herein refers to an oligopeptide, peptide, polypeptide or protein sequence.

10       "Peptide nucleic acid" as used herein refers to a molecule which comprises an oligomer to which an amino acid residue, such as lysine, and an amino group have been added. These small molecules, also designated anti-gene agents, stop transcript elongation by binding to their complementary (template) strand of nucleic acid (Nielsen PE et al (1993) Anticancer Drug Des 8:53-63).

15       A "variant" of IPKC may have an amino acid sequence that is different by one or more amino acid "substitutions". The variant may have "conservative" changes, wherein a substituted amino acid has similar structural or chemical properties, eg, replacement of leucine with isoleucine. More rarely, a variant may have "nonconservative" changes, eg, replacement of a glycine with a tryptophan. Similar minor variations may also include amino acid deletions or  
20 insertions, or both. Guidance in determining which and how many amino acid residues may be substituted, inserted or deleted without abolishing biological or immunological activity may be found using computer programs well known in the art, for example, DNASTar software.

      The term "biologically active" refers to a IPKC having structural, regulatory or biochemical functions of the naturally occurring IPKC. Likewise, "immunologically active"  
25 defines the capability of the natural, recombinant or synthetic IPKC, or any oligopeptide thereof, to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies.

      The term "derivative" as used herein refers to the chemical modification of a ipkc or the encoded IPKC. Illustrative of such modifications would be replacement of hydrogen by an alkyl,  
30 acyl, or amino group. A IPKC derivative would encode a polypeptide which retains essential biological characteristics of natural IPKC.

      As used herein, the term "purified" refers to molecules, either nucleic or amino acid

sequences, that are removed from their natural environment and isolated or separated from at least one other component with which they are naturally associated.

### **The IPKC Coding Sequences**

The nucleic acid and deduced amino acid sequences of IPKC are shown in Figures 1A and 1B. In accordance with the invention, any nucleic acid sequence which encodes the amino acid sequence of IPKC can be used to generate recombinant molecules which express IPKC. In a specific embodiment described herein, the sequence for ipkc was first isolated as Incyte Clone 75682 from a THP-1 cDNA library (THP1PEB01), Patent Application Serial No. 08/438,571 entitled "Polynucleotides Derived from THP-1 Cells" by Delegeane et al and filed May 10, 1995, the disclosure of which is incorporated herein by reference.

It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of IPKC-encoding nucleotide sequences, some bearing minimal homology to the nucleotide sequences of any known and naturally occurring gene may be produced. The invention has specifically contemplated each and every possible variation of nucleotide sequence that could be made by selecting combinations based on possible codon choices. These combinations are made in accordance with the standard triplet genetic code as applied to the nucleotide sequence of naturally occurring IPKC, and all such variations are to be considered as being specifically disclosed.

Although nucleotide sequences which encode IPKC and its variants are preferably capable of hybridizing to the nucleotide sequence of the naturally occurring ipkc under appropriately selected conditions of stringency, it may be advantageous to produce nucleotide sequences encoding IPKC or its derivatives possessing a substantially different codon usage. Codons may be selected to increase the rate at which expression of the peptide occurs in a particular prokaryotic or eukaryotic expression host in accordance with the frequency with which particular codons are utilized by the host. Other reasons for substantially altering the nucleotide sequence encoding IPKC and its derivatives without altering the encoded amino acid sequences include the production of RNA transcripts having more desirable properties, such as a greater half-life, than transcripts produced from the naturally occurring sequence.

It is now possible to produce a DNA sequence, or portions thereof, encoding a IPKC and its derivatives entirely by synthetic chemistry, after which the synthetic gene may be inserted into any of the many available DNA vectors and cell systems using reagents that are well known in the art at the time of the filing of this application. Moreover, synthetic chemistry may be used to

introduce mutations into a ipkc sequence or any portion thereof.

Also included within the scope of the present invention are polynucleotide sequences that are capable of hybridizing to the nucleotide sequence of Figures 1A and 1B under various conditions of stringency. Hybridization conditions are based on the melting temperature ( $T_m$ ) of the nucleic acid binding complex or probe, as taught in Berger and Kimmel (1987, Guide to Molecular Cloning Techniques, Methods in Enzymology, Vol 152, Academic Press, San Diego CA) incorporated herein by reference, and confer may be used at a defined "stringency" as explained below.

"Maximum stringency" typically occurs at about  $T_m - 5^\circ\text{C}$  ( $5^\circ\text{C}$  below the  $T_m$  of the probe); "high stringency" at about  $5^\circ\text{C}$  to  $10^\circ\text{C}$  below  $T_m$ ; "intermediate stringency" at about  $10^\circ\text{C}$  to  $20^\circ\text{C}$  below  $T_m$ ; and "low stringency" at about  $20^\circ\text{C}$  to  $25^\circ\text{C}$  below  $T_m$ . As will be understood by those of skill in the art, a maximum stringency hybridization can be used to identify or detect identical polynucleotide sequences while an intermediate (or low) stringency hybridization can be used to identify or detect similar or related polynucleotide sequences.

The term "hybridization" as used herein shall include "any process by which a strand of nucleic acid joins with a complementary strand through base pairing" (Coombs J (1994) Dictionary of Biotechnology, Stockton Press, New York NY). Amplification as carried out in the polymerase chain reaction technologies described in Dieffenbach CW and GS Dveksler (1995, PCR Primer, a Laboratory Manual, Cold Spring Harbor Press, Plainview NY) and incorporated herein by reference may follow the process of hybridization.

A "deletion" is defined as a change in either nucleotide or amino acid sequence in which one or more nucleotides or amino acid residues, respectively, are absent.

An "insertion" or "addition" is that change in a nucleotide or amino acid sequence which has resulted in the addition of one or more nucleotides or amino acid residues, respectively, as compared to the naturally occurring ipkc.

A "substitution" results from the replacement of one or more nucleotides or amino acids by different nucleotides or amino acids, respectively.

Altered ipkc nucleic acid sequences which may be used in accordance with the invention include deletions, insertions or substitutions of different nucleotides resulting in a polynucleotide that encodes the same or a functionally equivalent IPKC. The protein may also show deletions, insertions or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent IPKC. Deliberate amino acid substitutions may be made on the basis of

similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues as long as the biological activity of IPKC is retained. For example, negatively charged amino acids include aspartic acid and glutamic acid; positively charged amino acids include lysine and arginine; and amino acids with uncharged polar head groups having similar hydrophilicity values include leucine, isoleucine, valine; glycine, alanine; asparagine, glutamine; serine, threonine, phenylalanine, and tyrosine.

Included within the scope of the present invention are alleles of ipkc. As used herein, an "allele" or "allelic sequence" is an alternative form of ipkc. Alleles result from a mutation, ie, a change in the nucleic acid sequence, and generally produce altered mRNAs or polypeptides whose structure or function may or may not be altered. Any given gene may have none, one or many allelic forms. Common mutational changes which give rise to alleles are generally ascribed to natural deletions, additions or substitutions of amino acids. Each of these types of changes may occur alone, or in combination with the others, one or more times in a given sequence.

Methods for DNA sequencing are well known in the art and employ such enzymes as the Klenow fragment of DNA polymerase I, Sequenase® (US Biochemical Corp, Cleveland OH), Taq polymerase (Perkin Elmer, Norwalk CT), thermostable T7 polymerase (Amersham, Chicago IL), or combinations of recombinant polymerases and proofreading exonucleases such as the ELONGASE Amplification System marketed by Gibco BRL (Gaithersburg MD). Preferably, the process is automated with machines such as the Hamilton Micro Lab 2200 (Hamilton, Reno NV), Peltier Thermal Cycler (PTC200; MJ Research, Watertown MA) and the ABI 377 DNA sequencers (Perkin Elmer).

#### **Extending the Polynucleotide Sequence**

The polynucleotide sequence of ipkc may be extended utilizing partial nucleotide sequence and various methods known in the art to detect upstream sequences such as promoters and regulatory elements. Gobinda et al (1993; PCR Methods Applic 2:318-22) disclose "restriction-site" polymerase chain reaction (PCR) as a direct method which uses universal primers to retrieve unknown sequence adjacent to a known locus. First, genomic DNA is amplified in the presence of primer to a linker sequence and a primer specific to the known region. The amplified sequences are subjected to a second round of PCR with the same linker primer and another specific primer internal to the first one. Products of each round of PCR are transcribed with an appropriate RNA polymerase and sequenced using reverse transcriptase.

Inverse PCR can be used to amplify or extend sequences using divergent primers based on a known region (Triglia T et al (1988) Nucleic Acids Res 16:8186). The primers may be designed using OLIGO® 4.06 Primer Analysis Software (1992; National Biosciences Inc, Plymouth MN), or another appropriate program, to be 22-30 nucleotides in length, to have a GC content of 50% or more, and to anneal to the target sequence at temperatures about 68°-72° C. The method uses several restriction enzymes to generate a suitable fragment in the known region of a gene. The fragment is then circularized by intramolecular ligation and used as a PCR template.

Capture PCR (Lagerstrom M et al (1991) PCR Methods Applic 1:111-19) is a method for PCR amplification of DNA fragments adjacent to a known sequence in human and yeast artificial chromosome DNA. Capture PCR also requires multiple restriction enzyme digestions and ligations to place an engineered double-stranded sequence into an unknown portion of the DNA molecule before PCR.

Parker JD et al (1991; Nucleic Acids Res 19:3055-60), teach walking PCR, a method for targeted gene walking which permits retrieval of unknown sequence. PromoterFinder™ a new kit available from Clontech (Palo Alto CA) uses PCR, nested primers and PromoterFinder libraries to walk in genomic DNA. This process avoids the need to screen libraries and is useful in finding intron/exon junctions.

Preferred libraries for screening for full length cDNAs are ones that have been size-selected to include larger cDNAs. Also, random primed libraries are preferred in that they will contain more sequences which contain the 5' and upstream regions of genes. A randomly primed library may be particularly useful if an oligo d(T) library does not yield a full-length cDNA. Genomic libraries are useful for extension into the 5' nontranslated regulatory region.

A new method for analyzing either the size or confirming the nucleotide sequence of sequencing or PCR products is capillary electrophoresis. Systems for rapid sequencing are available from Perkin Elmer, Beckman Instruments (Fullerton CA), and other companies. Capillary sequencing employs flowable polymers for electrophoretic separation, four different fluorescent dyes (one for each nucleotide) which are laser activated, and detection of the emitted wavelengths by a charge coupled device camera. Output/light intensity is converted to electrical signal using appropriate software (eg. Genotyper™ and Sequence Navigator™ from Perkin Elmer) and the entire process from loading of samples to computer analysis and electronic data display is computer controlled. Capillary electrophoresis is particularly suited to the sequencing

of small pieces of DNA which might be present in limited amounts in a particular sample. The reproducible sequencing of up to 350 bp of M13 phage DNA in 30 min has been reported (Ruiz-Martinez MC et al (1993) Anal Chem 65:2851-8).

### **Expression of the Nucleotide Sequence**

- 5 In accordance with the present invention, polynucleotide sequences which encode IPKC, fragments of the polypeptide, fusion proteins or functional equivalents thereof may be used in recombinant DNA molecules that direct the expression of IPKC in appropriate host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences which encode substantially the same or a functionally equivalent amino acid sequence, may be used to clone and express IPKC.
- 10 As will be understood by those of skill in the art, it may be advantageous to produce IPKC-encoding nucleotide sequences possessing non-naturally occurring codons. Codons preferred by a particular prokaryotic or eukaryotic host (Murray E et al (1989) Nuc Acids Res 17:477-508) can be selected, for example, to increase the rate of IPKC expression or to produce recombinant RNA transcripts having desirable properties, such as a longer half-life, than transcripts produced
- 15 from naturally occurring sequence.

- The nucleotide sequences of the present invention can be engineered in order to alter a *ipkc* coding sequence for a variety of reasons, including but not limited to, alterations which modify the cloning, processing and/or expression of the gene product. For example, mutations may be introduced using techniques which are well known in the art, eg, site-directed
- 20 mutagenesis to insert new restriction sites, to alter glycosylation patterns, to change codon preference, to produce splice variants, etc.

- In another embodiment of the invention, a natural, modified or recombinant *ipkc* sequence may be ligated to a heterologous sequence to encode a fusion protein. For example, for screening of peptide libraries for inhibitors of IPKC activity, it may be useful to encode a
- 25 chimeric IPKC protein that is recognized by a commercially available antibody. A fusion protein may also be engineered to contain a cleavage site located between a IPKC sequence and the heterologous protein sequence, so that the IPKC may be cleaved and purified away from the heterologous moiety.

- In an alternate embodiment of the invention, the coding sequence of *ipkc* could be
- 30 synthesized, whole or in part, using chemical methods well known in the art (see Caruthers MH et al (1980) Nuc Acids Res Symp Ser 215-23, Horn T et al (1980) Nuc Acids Res Symp Ser 225-32, etc). Alternatively, the protein itself could be produced using chemical methods to synthesize

a IPKC amino acid sequence, whole or in part. For example, peptide synthesis can be performed using various solid-phase techniques (Roberge JY et al (1995) Science 269:202-204) and automated synthesis may be achieved, for example, using the ABI 431A Peptide Synthesizer (Perkin Elmer) in accordance with the instructions provided by the manufacturer.

5       The newly synthesized peptide can be purified by preparative high performance liquid chromatography (eg, Creighton (1983) Proteins, Structures and Molecular Principles, WH Freeman and Co, New York NY). The composition of the synthetic peptides may be confirmed by amino acid analysis or sequencing (eg, the Edman degradation procedure; Creighton, supra). Additionally the amino acid sequence of IPKC, or any part thereof, may be altered during direct  
10 synthesis and/or combined using chemical methods with sequences from other proteins, or any part thereof, to produce a variant polypeptide.

#### **Expression Systems**

In order to express a biologically active IPKC, the nucleotide sequence encoding IPKC or its functional equivalent, is inserted into an appropriate expression vector, ie, a vector which  
15 contains the necessary elements for the transcription and translation of the inserted coding sequence.

Methods which are well known to those skilled in the art can be used to construct expression vectors containing a IPKC coding sequence and appropriate transcriptional or translational controls. These methods include in vitro recombinant DNA techniques, synthetic  
20 techniques and in vivo recombination or genetic recombination. Such techniques are described in Sambrook et al (1989) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Plainview NY and Ausubel FM et al (1989) Current Protocols in Molecular Biology, John Wiley & Sons, New York NY.

A variety of expression vector/host systems may be utilized to contain and express a ipkc  
25 coding sequence. These include but are not limited to microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with virus expression vectors (eg, baculovirus); plant cell systems transfected with virus expression vectors (eg, cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with bacterial  
30 expression vectors (eg, Ti or pBR322 plasmid); or animal cell systems.

The "control elements" or "regulatory sequences" of these systems vary in their strength and specificities and are those nontranslated regions of the vector, enhancers, promoters, and 3'

untranslated regions, which interact with host cellular proteins to carry out transcription and translation. Depending on the vector system and host utilized, any number of suitable transcription and translation elements, including constitutive and inducible promoters, may be used. For example, when cloning in bacterial systems, inducible promoters such as the hybrid  
5 lacZ promoter of the Bluescript® phagemid (Stratagene, LaJolla CA) or pSport1 (Gibco BRL) and ptrp-lac hybrids and the like may be used. The baculovirus polyhedrin promoter may be used in insect cells. Promoters or enhancers derived from the genomes of plant cells (eg, heat shock, RUBISCO; and storage protein genes) or from plant viruses (eg, viral promoters or leader sequences) may be cloned into the vector. In mammalian cell systems, promoters from the  
10 mammalian genes or from mammalian viruses are most appropriate. If it is necessary to generate a cell line that contains multiple copies of ipkc, vectors based on SV40 or EBV may be used with an appropriate selectable marker.

In bacterial systems, a number of expression vectors may be selected depending upon the use intended for IPKC. For example, when large quantities of IPKC are needed for the induction  
15 of antibodies, vectors which direct high level expression of fusion proteins that are readily purified may be desirable. Such vectors include, but are not limited to, the multifunctional *E. coli* cloning and expression vectors such as Bluescript® (Stratagene), in which the ipkc coding sequence may be ligated into the vector in frame with sequences for the amino-terminal Met and the subsequent 7 residues of  $\beta$ -galactosidase so that a hybrid protein is produced; pIN vectors  
20 (Van Heeke & Schuster (1989) J Biol Chem 264:5503-5509); and the like. pGEX vectors (Promega, Madison WI) may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption to glutathione-agarose beads followed by elution in the presence of free glutathione. Proteins made in such systems are designed to include heparin,  
25 thrombin or factor XA protease cleavage sites so that the cloned polypeptide of interest can be released from the GST moiety at will.

In the yeast, *Saccharomyces cerevisiae*, a number of vectors containing constitutive or inducible promoters such as alpha factor, alcohol oxidase and PGH may be used. For reviews, see Ausubel et al (supra) and Grant et al (1987) Methods in Enzymology 153:516-544.

30 In cases where plant expression vectors are used, the expression of a sequence encoding IPKC may be driven by any of a number of promoters. For example, viral promoters such as the 35S and 19S promoters of CaMV (Brisson et al (1984) Nature 310:511-514) may be used alone



or in combination with the omega leader sequence from TMV (Takamatsu et al (1987) EMBO J 6:307-311). Alternatively, plant promoters such as the small subunit of RUBISCO (Coruzzi et al (1984) EMBO J 3:1671-1680; Broglie et al (1984) Science 224:838-843); or heat shock promoters (Winter J and Sinibaldi RM (1991) Results Probl Cell Differ 17:85-105) may be used.

5 These constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection. For reviews of such techniques, see Hobbs S or Murry LE in McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill New York NY, pp 191-196 or Weissbach and Weissbach (1988) Methods for Plant Molecular Biology, Academic Press, New York NY, pp 421-463.

10 An alternative expression system which could be used to express ipkc is an insect system. In one such system, Autographa californica nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes in Spodoptera frugiperda cells or in Trichoplusia larvae. The ipkc coding sequence may be cloned into a nonessential region of the virus, such as the polyhedrin gene, and placed under control of the polyhedrin promoter. Successful insertion of ipkc will  
15 render the polyhedrin gene inactive and produce recombinant virus lacking coat protein coat. The recombinant viruses are then used to infect S. frugiperda cells or Trichoplusia larvae in which IPKC is expressed (Smith et al (1983) J Virol 46:584; Engelhard EK et al (1994) Proc Nat Acad Sci 91:3224-7).

In mammalian host cells, a number of viral-based expression systems may be utilized. In  
20 cases where an adenovirus is used as an expression vector, a ipkc coding sequence may be ligated into an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a nonessential E1 or E3 region of the viral genome will result in a viable virus capable of expressing IPKC in infected host cells. (Logan and Shenk (1984) Proc Natl Acad Sci 81:3655-59). In addition, transcription enhancers, such as the rous sarcoma virus  
25 (RSV) enhancer, may be used to increase expression in mammalian host cells.

Specific initiation signals may also be required for efficient translation of a ipkc sequence. These signals include the ATG initiation codon and adjacent sequences. In cases where ipkc, its initiation codon and upstream sequences are inserted into the appropriate expression vector, no additional translational control signals may be needed. However, in cases where only coding  
30 sequence, or a portion thereof, is inserted, exogenous transcriptional control signals including the ATG initiation codon must be provided. Furthermore, the initiation codon must be in the correct reading frame to ensure transcription of the entire insert. Exogenous transcriptional elements and

initiation codons can be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers appropriate to the cell system in use (Scharf D et al (1994) Results Probl Cell Differ 20:125-62; Bittner et al (1987) Methods in Enzymol 153:516-544).

5 In addition, a host cell strain may be chosen for its ability to modulate the expression of the inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation and acylation. Post-translational processing which cleaves a "prepro" form of the protein may also be important for correct insertion, folding and/or  
10 function. Different host cells such as CHO, HeLa, MDCK, 293, WI38, etc have specific cellular machinery and characteristic mechanisms for such post-translational activities and may be chosen to ensure the correct modification and processing of the introduced, foreign protein.

For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines which stably express ipkc may be transformed using  
15 expression vectors which contain viral origins of replication or endogenous expression elements and a selectable marker gene. Following the introduction of the vector, cells may be allowed to grow for 1-2 days in an enriched media before they are switched to selective media. The purpose of the selectable marker is to confer resistance to selection, and its presence allows growth and recovery of cells which successfully express the introduced sequences. Resistant clumps of  
20 stably transformed cells can be proliferated using tissue culture techniques appropriate to the cell type.

Any number of selection systems may be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase (Wigler M et al (1977) Cell 11:223-32) and adenine phosphoribosyltransferase (Lowy I et al (1980) Cell 22:817-23)  
25 genes which can be employed in tk- or aprt- cells, respectively. Also, antimetabolite, antibiotic or herbicide resistance can be used as the basis for selection; for example, dhfr which confers resistance to methotrexate (Wigler M et al (1980) Proc Natl Acad Sci 77:3567-70); npt, which confers resistance to the aminoglycosides neomycin and G-418 (Colbere-Garapin F et al (1981) J Mol Biol 150:1-14) and als or pat, which confer resistance to chlorsulfuron and phosphinotricin  
30 acetyltransferase, respectively (Murry, supra). Additional selectable genes have been described, for example, trpB, which allows cells to utilize indole in place of tryptophan, or hisD, which allows cells to utilize histinol in place of histidine (Hartman SC and RC Mulligan (1988) Proc

Natl Acad Sci 85:8047-51). Recently, the use of visible markers has gained popularity with such markers as anthocyanins,  $\beta$  glucuronidase and its substrate, GUS, and luciferase and its substrate, luciferin, being widely used not only to identify transformants, but also to quantify the amount of transient or stable protein expression attributable to a specific vector system (Rhodes CA et al 5 (1995) Methods Mol Biol 55:121-131).

#### **Identification of Transformants Containing the Polynucleotide Sequence**

Although the presence/absence of marker gene expression suggests that the gene of interest is also present, its presence and expression should be confirmed. For example, if the ipkc is inserted within a marker gene sequence, recombinant cells containing ipkc can be identified by 10 the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a IPKC sequence under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the tandem ipkc as well.

Alternatively, host cells which contain the coding sequence for ipkc and express IPKC may be identified by a variety of procedures known to those of skill in the art. These procedures 15 include, but are not limited to, DNA-DNA or DNA-RNA hybridization and protein bioassay or immunoassay techniques which include membrane, solution, or chip based technologies for the detection and/or quantification of the nucleic acid or protein.

The presence of the ipkc polynucleotide sequence can be detected by DNA-DNA or DNA-RNA hybridization or amplification using probes, portions or fragments of ipkc. Nucleic 20 acid amplification based assays involve the use of oligonucleotides or oligomers based on the ipkc sequence to detect transformants containing ipkc DNA or RNA. As used herein "oligonucleotides" or "oligomers" refer to a nucleic acid sequence of at least about 10 nucleotides and as many as about 60 nucleotides, preferably about 15 to 30 nucleotides, and more preferably about 20-25 nucleotides which can be used as a probe or amplifier.

25 A variety of protocols for detecting and measuring the expression of IPKC, using either polyclonal or monoclonal antibodies specific for the protein are known in the art. Examples include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA) and fluorescent activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on IPKC is preferred, but a competitive 30 binding assay may be employed. These and other assays are described, among other places, in Hampton R et al (1990, Serological Methods, a Laboratory Manual, APS Press, St Paul MN) and Maddox DE et al (1983, J Exp Med 158:1211).

A wide variety of labels and conjugation techniques are known by those skilled in the art and can be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting sequences related to ipkc include oligolabeling, nick translation, end-labeling or PCR amplification using a labeled nucleotide. Alternatively, the ipkc sequence, or any portion of it, may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by addition of an appropriate RNA polymerase such as T7, T3 or SP6 and labeled nucleotides.

A number of companies such as Pharmacia Biotech (Piscataway NJ), Promega (Madison WI), and US Biochemical Corp (Cleveland OH) supply commercial kits and protocols for these procedures. Suitable reporter molecules or labels include those radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents as well as substrates, cofactors, inhibitors, magnetic particles and the like. Patents teaching the use of such labels include US Patents 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; 4,275,149 and 4,366,241. Also, recombinant immunoglobulins may be produced as shown in US Patent No. 4,816,567 incorporated herein by reference.

#### **Purification of IPKC**

Host cells transformed with a ipkc nucleotide sequence may be cultured under conditions suitable for the expression and recovery of the encoded protein from cell culture. The protein produced by a recombinant cell may be secreted or contained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing ipkc can be designed with signal sequences which direct secretion of IPKC through a prokaryotic or eukaryotic cell membrane. Other recombinant constructions may join ipkc to nucleotide sequence encoding a polypeptide domain which will facilitate purification of soluble proteins (Kroll DJ et al (1993) DNA Cell Biol 12:441-53; cf discussion of vectors infra containing fusion proteins).

IPKC may also be expressed as a recombinant protein with one or more additional polypeptide domains added to facilitate protein purification. Such purification facilitating domains include, but are not limited to, metal chelating peptides such as histidine-tryptophan modules that allow purification on immobilized metals, protein A domains that allow purification on immobilized immunoglobulin, and the domain utilized in the FLAGS extension/affinity purification system (Immunex Corp, Seattle WA). The inclusion of a cleavable linker sequences

such as Factor XA or enterokinase (Invitrogen, San Diego CA) between the purification domain and IPKC is useful to facilitate purification. One such expression vector provides for expression of a fusion protein comprising an IPKC and contains nucleic acid encoding 6 histidine residues followed by thioredoxin and an enterokinase cleavage site. The histidine residues  
5 facilitate purification on IMIAC (immobilized metal ion affinity chromatography as described in Porath et al (1992) Protein Expression and Purification 3: 263-281) while the enterokinase cleavage site provides a means for purifying the chemokine from the fusion protein.

In addition to recombinant production, fragments of IPKC may be produced by direct peptide synthesis using solid-phase techniques (cf Stewart et al (1969) Solid-Phase Peptide  
10 Synthesis, WH Freeman Co, San Francisco; Merrifield J (1963) J Am Chem Soc 85:2149-2154). In vitro protein synthesis may be performed using manual techniques or by automation. Automated synthesis may be achieved, for example, using Applied Biosystems 431A Peptide Synthesizer (Perkin Elmer, Foster City CA) in accordance with the instructions provided by the manufacturer. Various fragments of IPKC may be chemically synthesized separately and  
15 combined using chemical methods to produce the full length molecule.

#### Uses of IPKC

The rationale for use of the nucleotide and polypeptide sequences disclosed herein is based in part on the chemical and structural homology among the novel human IPKC disclosed herein, the putative protein kinase C inhibitor (GI 493051; Waller and Murphy, supra), and  
20 PKCI-1 (Brzoska et al (1995) PNAS USA 92: 7824-7828; Fig. 4).

PKC activation plays a major role in multidrug resistance (MDR), which is a major contributing factor in the failure of many chemotherapeutic cancer regimens (Grunicke H et al (1994) Ann Hematol 69:S1-6). Therefore, IPKC or an IPKC derivative may be used to downregulate PKC activity thus diminishing MDR while maintaining the sensitivity of tumor  
25 cells to chemotherapy.

Zhang et al showed that the PKC inhibitor, hypericin, induces apoptosis in human neuroblastoma SK-N-SH cells (1995; Cancer Lett 96:31-35). Therefore, IPKC may be used therapeutically to induce cell death in neuroblastomas.

O'Brian CA et al (1995; Prog Clin Biol Res 391: 117-120) found evidence that the  
30 induction of resistance to chemotherapy in human colon cancers is mediated by PKC and suggest that the selective inhibition of cPKC alpha might allow successful management of colon cancer with standard cytotoxic chemotherapeutic regimens. Therefore, IPKC or an IPKC derived

molecule, may be used therapeutically in the management of colon cancer.

Zong Z et al (1996; Biochem Biophys Res Commun 219:480-485) found that saikosponin b2 induces apoptosis in B16 melanoma cells by down regulation of PKC activity. Therefore, IPKC or an IPKC derived molecule may be used to treat melanomas.

5 PKC inhibitors have been shown to trigger apoptosis in a large number of cancer cell lines. Therefore, inhibitors of PKC, including IPKC, may be used in the treatment of a variety of cancers. Pearson et al (supra) suggest that endogenous inhibitors, such as IPKC, may have greater specificity for PKC thereby resulting in fewer toxicities and greater efficacy than synthetic inhibitors.

10 In those disorders where the induction of apoptosis is desirable, IPKC could be used to trigger apoptosis. The ipkc gene could be targetted to and expressed within a cell type to induce apoptosis. Alternatively, IPKC or an IPKC derivative could be delivered to particular cells through a number of targeting techniques. Apoptosis is desirable in auto-immune disorders such as rheumatoid arthritis, multiple sclerosis, and myasthenia gravis, and cancers such as lymphoma,  
15 intestinal and breast cancer.

Additionally, because the cellular distribution of PKCs changes as a result of memory storage in cells that have been demonstrated to act in memory and learning (Saito N et al, supra) IPKC or an IPKC derivative, through its affects on PKC activity, may be used to slow, stop, or reverse a decline in memory such as seen in Alzheimer's disease or in learning abilities.

## 20 IPKC Antibodies

IPKC-specific antibodies are useful for the diagnosis of conditions and diseases associated with expression of IPKC. IPKC for antibody induction does not require biological activity; however, the protein fragment, or oligopeptide must be antigenic. Peptides used to induce specific antibodies may have an amino acid sequence consisting of at least five amino  
25 acids, preferably at least 10 amino acids. They should mimic a portion of the amino acid sequence of the natural protein and may contain the entire amino acid sequence of a small, naturally occurring molecule. Short stretches of IPKC amino acids may be fused with those of another protein such as keyhole limpet hemocyanin and antibody produced against the chimeric molecule. Procedures well known in the art can be used for the production of antibodies to IPKC  
30 Such antibodies include, but are not limited to, polyclonal, monoclonal, chimeric, single chain, Fab fragments and fragments produced by a Fab expression library. Neutralizing antibodies, ie, those which inhibit dimer formation, are especially preferred for diagnostics and therapeutics.

For the production of antibodies, various hosts including goats, rabbits, rats, mice, etc may be immunized by injection with IPKC or any portion, fragment or oligopeptide which retains immunogenic properties. Depending on the host species, various adjuvants may be used to increase immunological response. Such adjuvants include but are not limited to Freund's, 5 mineral gels such as aluminum hydroxide, and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, and dinitrophenol. BCG (bacilli Calmette-Guerin) and Corynebacterium parvum are potentially useful human adjuvants.

Monoclonal antibodies to IPKC may be prepared using any technique which provides for 10 the production of antibody molecules by continuous cell lines in culture. These include but are not limited to the hybridoma technique originally described by Koehler and Milstein (1975 Nature 256:495-497), the human B-cell hybridoma technique (Kosbor et al (1983) Immunol Today 4:72; Cote et al (1983) Proc Natl Acad Sci 80:2026-2030) and the EBV-hybridoma technique (Cole et al (1985) Monoclonal Antibodies and Cancer Therapy, Alan R Liss Inc, New 15 York NY, pp 77-96).

In addition, techniques developed for the production of "chimeric antibodies", the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity can be used (Morrison et al (1984) Proc Natl Acad Sci 81:6851-6855; Neuberger et al (1984) Nature 312:604-608; Takeda et al (1985) Nature 314:452- 20 454). Alternatively, techniques described for the production of single chain antibodies (US Patent No. 4,946,778) can be adapted to produce IPKC-specific single chain antibodies

Antibodies may also be produced by inducing in vivo production in the lymphocyte population or by screening recombinant immunoglobulin libraries or panels of highly specific binding reagents as disclosed in Orlandi et al (1989, Proc Natl Acad Sci 86: 3833-3837), and 25 Winter G and Milstein C (1991; Nature 349:293-299).

Antibody fragments which contain specific binding sites for IPKC may also be generated. For example, such fragments include, but are not limited to, the F(ab')<sub>2</sub> fragments which can be produced by pepsin digestion of the antibody molecule and the Fab fragments which can be generated by reducing the disulfide bridges of the F(ab')<sub>2</sub> fragments. Alternatively, Fab 30 expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity (Huse WD et al (1989) Science 256:1275-1281).

A variety of protocols for competitive binding or immunoradiometric assays using either

polyclonal or monoclonal antibodies with established specificities are well known in the art. Such immunoassays typically involve the formation of complexes between IPKC and its specific antibody and the measurement of complex formation. A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two noninterfering epitopes on a  
5 specific IPKC protein is preferred, but a competitive binding assay may also be employed. These assays are described in Maddox DE et al (1983, J Exp Med 158:1211).

#### **Diagnostic Assays Using IPKC Specific Antibodies**

Particular IPKC antibodies are useful for the diagnosis of conditions or diseases characterized by expression of IPKC or in assays to monitor patients being treated with IPKC,  
10 agonists or inhibitors. Diagnostic assays for IPKC include methods utilizing the antibody and a label to detect IPKC in human body fluids or extracts of cells or tissues. The polypeptides and antibodies of the present invention may be used with or without modification. Frequently, the polypeptides and antibodies will be labeled by joining them, either covalently or noncovalently, with a reporter molecule. A wide variety of reporter molecules are known, several of which were  
15 described above.

A variety of protocols for measuring IPKC, using either polyclonal or monoclonal antibodies specific for the respective protein are known in the art. Examples include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA) and fluorescent activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies  
20 reactive to two non-interfering epitopes on IPKC is preferred, but a competitive binding assay may be employed. These assays are described, among other places, in Maddox, DE et al (1983, J Exp Med 158:1211).

In order to provide a basis for diagnosis, normal or standard values for IPKC expression must be established. This is accomplished by combining body fluids or cell extracts taken from  
25 normal subjects, either animal or human, with antibody to IPKC under conditions suitable for complex formation which are well known in the art. The amount of standard complex formation may be quantified by comparing various artificial membranes containing known quantities of IPKC with both control and disease samples from biopsied tissues. Then, standard values obtained from normal samples may be compared with values obtained from samples from  
30 subjects potentially affected by disease. Deviation between standard and subject values establishes the presence of disease state.



### Drug Screening

IPKC, its catalytic or immunogenic fragments or oligopeptides thereof, can be used for screening therapeutic compounds in any of a variety of drug screening techniques. The fragment employed in such a test may be free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. The formation of binding complexes, between IPKC and the agent being tested, may be measured.

Another technique for drug screening which provides for high throughput screening of compounds having suitable binding affinity to the IPKC is described in detail in "Determination of Amino Acid Sequence Antigenicity" by Geysen HN, WO Application 84/03564, published on September 13, 1984, and incorporated herein by reference. In summary, large numbers of different small peptide test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. The peptide test compounds are reacted with fragments of IPKC and washed. Bound IPKC is then detected by methods well known in the art. Purified IPKC can also be coated directly onto plates for use in the aforementioned drug screening techniques. Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support.

This invention also contemplates the use of competitive drug screening assays in which neutralizing antibodies capable of binding IPKC specifically compete with a test compound for binding IPKC. In this manner, the antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants with IPKC.

### Uses of the Polynucleotide Encoding IPKC

A polynucleotide, ipkc, or any part thereof, may be used for diagnostic and/or therapeutic purposes. For diagnostic purposes, the ipkc of this invention may be used to detect and quantitate gene expression in biopsied tissues in which expression of IPKC may be implicated. The diagnostic assay is useful to distinguish between absence, presence, and excess expression of ipkc and to monitor regulation of ipkc levels during therapeutic intervention. Included in the scope of the invention are oligonucleotide sequences, antisense RNA and DNA molecules, and PNAs.

Another aspect of the subject invention is to provide for hybridization or PCR probes which are capable of detecting polynucleotide sequences, including genomic sequences, encoding IPKC or closely related molecules. The specificity of the probe, whether it is made from a highly specific region, eg, 10 unique nucleotides in the 5' regulatory region, or a less specific region, eg,

especially in the 3' region, and the stringency of the hybridization or amplification (maximal, high, intermediate or low) will determine whether the probe identifies only naturally occurring ipkc, alleles or related sequences.

It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of IPKC-encoding nucleotide sequences, some bearing minimal  
5      homology to the nucleotide sequences of any known and naturally occurring gene may be produced. The invention has specifically contemplated each and every possible variation of nucleotide sequence that could be made by selecting combinations based on possible codon choices. These combinations are made in accordance with the standard triplet genetic code as  
10     applied to the nucleotide sequence of naturally occurring IPKC, and all such variations are to be considered as being specifically disclosed.

Probes may also be used for the detection of related inhibitor encoding sequences and should preferably contain at least 50% of the nucleotides from any of these IPKC encoding sequences. The hybridization probes of the subject invention may be derived from the nucleotide  
15     sequence of the SEQ ID NOs:1 and 3-7 or from genomic sequence including promoter, enhancer elements and introns of the naturally occurring ipkc. Hybridization probes may be labeled by a variety of reporter groups, including radionuclides such as 32P or 35S, or enzymatic labels such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems, and the like.

Other means for producing specific hybridization probes for ipkc DNAs include the  
20     cloning of nucleic acid sequences encoding IPKC or IPKC derivatives into vectors for the production of mRNA probes. Such vectors are known in the art and are commercially available and may be used to synthesize RNA probes in vitro by means of the addition of the appropriate RNA polymerase as T7 or SP6 RNA polymerase and the appropriate radioactively labeled nucleotides.

## 25     **Diagnostics**

Polynucleotide sequences encoding IPKC may be used for the diagnosis of conditions or diseases with which the expression of IPKC is associated. For example, polynucleotide sequences encoding IPKC may be used in hybridization or PCR assays of fluids or tissues from biopsies to detect ipkc expression. The form of such qualitative or quantitative methods may  
30     include Southern or northern analysis, dot blot or other membrane-based technologies; PCR technologies; dip stick, pin, chip and ELISA technologies. All of these techniques are well known in the art and are the basis of many commercially available diagnostic kits.

The ipkc nucleotide sequences disclosed herein provide the basis for assays that detect activation or induction associated with inflammation or disease. The ipkc nucleotide sequence may be labeled by methods known in the art and added to a fluid or tissue sample from a patient under conditions suitable for the formation of hybridization complexes. After an incubation  
5 period, the sample is washed with a compatible fluid which optionally contains a dye (or other label requiring a developer) if the nucleotide has been labeled with an enzyme. After the compatible fluid is rinsed off, the dye is quantitated and compared with a standard. If the amount of dye in the biopsied or extracted sample is significantly elevated over that of a comparable control sample, the nucleotide sequence has hybridized with nucleotide sequences in the sample,  
10 and the presence of elevated levels of ipkc nucleotide sequences in the sample indicates the presence of the associated inflammation and/or disease.

Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regime in animal studies, in clinical trials, or in monitoring the treatment of an individual patient. In order to provide a basis for the diagnosis of disease, a normal or standard profile for ipkc  
15 expression must be established. This is accomplished by combining body fluids or cell extracts taken from normal subjects, either animal or human, with ipkc, or a portion thereof, under conditions suitable for hybridization or amplification. Standard hybridization may be quantified by comparing the values obtained for normal subjects with a dilution series of ipkc run in the same experiment where a known amount of purified ipkc is used. Standard values obtained from  
20 normal samples may be compared with values obtained from samples from patients affected by ipkc-associated diseases. Deviation between standard and subject values establishes the presence of disease.

Once disease is established, a therapeutic agent is administered and a treatment profile is generated. Such assays may be repeated on a regular basis to evaluate whether the values in the  
25 profile progress toward or return to the normal or standard pattern. Successive treatment profiles may be used to show the efficacy of treatment over a period of several days or several months.

PCR as described in US Patent Nos. 4,683,195 and 4,965,188 provides additional uses for oligonucleotides based upon the ipkc sequence. Such oligomers are generally chemically synthesized, but they may be generated enzymatically or produced from a recombinant source.  
30 Oligomers generally comprise two nucleotide sequences, one with sense orientation (5'→3') and one with antisense (3'←5'), employed under optimized conditions for identification of a specific gene or condition. The same two oligomers, nested sets of oligomers, or even a degenerate pool

of oligomers may be employed under less stringent conditions for detection and/or quantitation of closely related DNA or RNA sequences.

Additionally, methods to quantitate the expression of a particular molecule include radiolabeling (Melby PC et al 1993 J Immunol Methods 159:235-44) or biotinylating (Duplaa C  
5 et al 1993 Anal Biochem 229-36) nucleotides, coamplification of a control nucleic acid, and standard curves onto which the experimental results are interpolated. Quantitation of multiple samples may be speeded up by running the assay in an ELISA format where the oligomer of interest is presented in various dilutions and a spectrophotometric or colorimetric response gives rapid quantitation. For example, the presence of ipkc in extracts of biopsied tissues may indicate  
10 the onset of cancer. A definitive diagnosis of this type may allow health professionals to begin aggressive treatment and prevent further worsening of the condition. Similarly, further assays can be used to monitor the progress of a patient during treatment. Furthermore, the nucleotide sequences disclosed herein may be used in molecular biology techniques that have not yet been developed, provided the new techniques rely on properties of nucleotide sequences that are  
15 currently known such as the triplet genetic code, specific base pair interactions, and the like.

#### **Therapeutics**

The cDNA made from human monocyte line THP-1 may be useful in the treatment of conditions associated with the libraries (shown in the Sequence ID Listing) which contained partial ipkc sequences. These include, but are not limited to, conditions such as, lymphoma,  
20 melanoma, breast, and colon cancer, and autoimmune diseases such as multiple sclerosis, rheumatoid arthritis, and myasthenia gravis.

Expression vectors derived from retroviruses, adenovirus, herpes or vaccinia viruses, or from various bacterial plasmids, may be used for delivery of nucleotide sequences to the targeted organ, tissue or cell population. Methods which are well known to those skilled in the art can be  
25 used to construct recombinant vectors which will express antisense ipkc. See, for example, the techniques described in Sambrook et al (supra) and Ausubel et al (supra).

The polynucleotides comprising full length cDNA sequence and/or its regulatory elements enable researchers to use ipkc as an investigative tool in sense (Youssoufian H and HF  
Lodish 1993 Mol Cell Biol 13:98-104) or antisense (Eguchi et al (1991) Annu Rev Biochem  
30 60:631-652) regulation of gene function. Such technology is now well known in the art, and sense or antisense oligomers, or larger fragments, can be designed from various locations along the coding or control regions.

Genes encoding IPKC can be turned off by transfecting a cell or tissue with expression vectors which express high levels of the desired ipkc fragment. Such constructs can flood cells with untranslatable sense or antisense sequences. Even in the absence of integration into the DNA, such vectors may continue to transcribe RNA molecules until all copies are disabled by  
5 endogenous nucleases. Transient expression may last for a month or more with a non-replicating vector (Mettler I, personal communication) and even longer if appropriate replication elements are part of the vector system.

As mentioned above, modifications of gene expression can be obtained by designing antisense molecules, DNA, RNA or PNA, to the control regions of ipkc, ie, the promoters,  
10 enhancers, and introns. Oligonucleotides derived from the transcription initiation site, eg, between -10 and +10 regions of the leader sequence, are preferred. The antisense molecules may also be designed to block translation of mRNA by preventing the transcript from binding to ribosomes. Similarly, inhibition can be achieved using "triple helix" base-pairing methodology. Triple helix pairing compromises the ability of the double helix to open sufficiently for the  
15 binding of polymerases, transcription factors, or regulatory molecules. Recent therapeutic advances using triplex DNA were reviewed by Gee JE et al (In: Huber BE and BI Carr (1994) Molecular and Immunologic Approaches, Futura Publishing Co, Mt Kisco NY).

Ribozymes are enzymatic RNA molecules capable of catalyzing the specific cleavage of RNA. The mechanism of ribozyme action involves sequence-specific hybridization of the  
20 ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. Within the scope of the invention are engineered hammerhead motif ribozyme molecules that can specifically and efficiently catalyze endonucleolytic cleavage of ipkc.

Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites which include the following  
25 sequences, GUA, GUU and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides corresponding to the region of the target gene containing the cleavage site may be evaluated for secondary structural features which may render the oligonucleotide inoperable. The suitability of candidate targets may also be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays.

30 Antisense molecules and ribozymes of the invention may be prepared by any method known in the art for the synthesis of RNA molecules. These include techniques for chemically synthesizing oligonucleotides such as solid phase phosphoramidite chemical synthesis.

Alternatively, RNA molecules may be generated by in vitro and in vivo transcription of DNA sequences encoding IPKC. Such DNA sequences may be incorporated into a wide variety of vectors with suitable RNA polymerase promoters such as T7 or SP6. Alternatively, antisense cDNA constructs that synthesize antisense RNA constitutively or inducibly can be introduced  
5 into cell lines, cells or tissues.

RNA molecules may be modified to increase intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3' ends of the molecule or the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages within the backbone of the molecule. This concept is inherent in the production of  
10 PNAs and can be extended in all of these molecules by the inclusion of nontraditional bases such as inosine, queosine and wybutosine as well as acetyl-, methyl-, thio- and similarly modified forms of adenine, cytidine, guanine, thymine, and uridine which are not as easily recognized by endogenous endonucleases.

Methods for introducing vectors into cells or tissues include those methods discussed  
15 infra and which are equally suitable for in vivo, in vitro and ex vivo therapy. For ex vivo therapy, vectors are introduced into stem cells taken from the patient and clonally propagated for autologous transplant back into that same patient is presented in US Patent Nos. 5,399,493 and 5,437,994, disclosed herein by reference. Delivery by transfection and by liposome are quite well known in the art.

20 Furthermore, the nucleotide sequences for ipkc disclosed herein may be used in molecular biology techniques that have not yet been developed, provided the new techniques rely on properties of nucleotide sequences that are currently known, including but not limited to such properties as the triplet genetic code and specific base pair interactions.

#### **Detection and Mapping of Related Polynucleotide Sequences**

25 The nucleic acid sequence for ipkc can also be used to generate hybridization probes for mapping the naturally occurring genomic sequence. The sequence may be mapped to a particular chromosome or to a specific region of the chromosome using well known techniques. These include in situ hybridization to chromosomal spreads, flow-sorted chromosomal preparations, or artificial chromosome constructions such as yeast artificial chromosomes, bacterial artificial  
30 chromosomes, bacterial P1 constructions or single chromosome cDNA libraries as reviewed in Price CM (1993; Blood Rev 7:127-34) and Trask BJ (1991; Trends Genet 7:149-54).

The technique of fluorescent in situ hybridization of chromosome spreads has been

described, among other places, in Verma et al (1988) Human Chromosomes: A Manual of Basic Techniques, Pergamon Press, New York NY. Fluorescent in situ hybridization of chromosomal preparations and other physical chromosome mapping techniques may be correlated with additional genetic map data. Examples of genetic map data can be found in the 1994 Genome

5 Issue of Science (265:1981f). Correlation between the location of a ipkc on a physical chromosomal map and a specific disease (or predisposition to a specific disease) may help delimit the region of DNA associated with that genetic disease. The nucleotide sequences of the subject invention may be used to detect differences in gene sequences between normal, carrier or affected individuals.

- 10 In situ hybridization of chromosomal preparations and physical mapping techniques such as linkage analysis using established chromosomal markers are invaluable in extending genetic maps. A recent example of an STS based map of the human genome was recently published by the Whitehead-MIT Center for Genomic Research (Hudson TJ et al (1995) Science 270:1945-1954). Often the placement of a gene on the chromosome of another mammalian species such as
- 15 mouse (Whitehead Institute/MIT Center for Genome Research, Genetic Map of the Mouse, Database Release 10, April 28, 1995) may reveal associated markers even if the number or arm of a particular human chromosome is not known. New sequences can be assigned to chromosomal arms, or parts thereof, by physical mapping. This provides valuable information to investigators searching for disease genes using positional cloning or other gene discovery techniques. Once a
- 20 disease or syndrome, such as ataxia telangiectasia (AT), has been crudely localized by genetic linkage to a particular genomic region, for example, AT to 11q22-23 (Gatti et al (1988) Nature 336:577-580), any sequences mapping to that area may represent associated or regulatory genes for further investigation. The nucleotide sequence of the subject invention may also be used to detect differences in the chromosomal location due to translocation, inversion, etc. among
- 25 normal, carrier or affected individuals.

### **Pharmaceutical Compositions**

- The present invention comprises pharmaceutical compositions which may comprise nucleotides, proteins, antibodies, antagonists, or inhibitors, alone or in combination with at least one other agent, such as stabilizing compound, which may be administered in any sterile,
- 30 biocompatible pharmaceutical carrier, including, but not limited to, saline, buffered saline, dextrose, and water. Any of these molecules can be administered to a patient alone, or in combination with other agents, drugs or hormones, in pharmaceutical compositions where it is

mixed with excipient(s) or pharmaceutically acceptable carriers. In one embodiment of the present invention, the pharmaceutically acceptable carrier is pharmaceutically inert.

#### **Administration of Pharmaceutical Compositions**

Administration of pharmaceutical compositions is accomplished orally or parenterally.

5 Methods of parenteral delivery include topical, intra-arterial (directly to the tumor), intramuscular, subcutaneous, intramedullary, intrathecal, intraventricular, intravenous, intraperitoneal, or intranasal administration. In addition to the active ingredients, these pharmaceutical compositions may contain suitable pharmaceutically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into  
10 preparations which can be used pharmaceutically. Further details on techniques for formulation and administration may be found in the latest edition of "Remington's Pharmaceutical Sciences" (Maack Publishing Co, Easton PA).

Pharmaceutical compositions for oral administration can be formulated using pharmaceutically acceptable carriers well known in the art in dosages suitable for oral  
15 administration. Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for ingestion by the patient.

Pharmaceutical preparations for oral use can be obtained through combination of active compounds with solid excipient, optionally grinding a resulting mixture, and processing the  
20 mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are carbohydrate or protein fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; starch from corn, wheat, rice, potato, or other plants; cellulose such as methyl cellulose, hydroxypropylmethyl-cellulose, or sodium carboxymethylcellulose; and gums including arabic and tragacanth; and proteins such as gelatin and collagen. If desired,  
25 disintegrating or solubilizing agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, alginic acid, or a salt thereof, such as sodium alginate.

Dragee cores are provided with suitable coatings such as concentrated sugar solutions, which may also contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent  
30 mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for product identification or to characterize the quantity of active compound, ie, dosage.

Pharmaceutical preparations which can be used orally include push-fit capsules made of



gelatin, as well as soft, sealed capsules made of gelatin and a coating such as glycerol or sorbitol. Push-fit capsules can contain active ingredients mixed with a filler or binders such as lactose or starches, lubricants such as talc or magnesium stearate, and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty  
5 oils, liquid paraffin, or liquid polyethylene glycol with or without stabilizers.

Pharmaceutical formulations for parenteral administration include aqueous solutions of active compounds. For injection, the pharmaceutical compositions of the invention may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks's solution, Ringer's solution, or physiologically buffered saline. Aqueous injection  
10 suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Optionally, the suspension may also contain suitable  
15 stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.

For topical or nasal administration, penetrants appropriate to the particular barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

#### **Manufacture and Storage**

20 The pharmaceutical compositions of the present invention may be manufactured in a manner that known in the art, eg, by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes.

The pharmaceutical composition may be provided as a salt and can be formed with many acids, including but not limited to hydrochloric, sulfuric, acetic, lactic, tartaric, malic, succinic,  
25 etc. Salts tend to be more soluble in aqueous or other protonic solvents than are the corresponding free base forms. In other cases, the preferred preparation may be a lyophilized powder in 1mM-50 mM histidine, 0.1%-2% sucrose, 2%-7% mannitol at a pH range of 4.5 to 5.5 that is combined with buffer prior to use.

After pharmaceutical compositions comprising a compound of the invention formulated  
30 in a acceptable carrier have been prepared, they can be placed in an appropriate container and labeled for treatment of an indicated condition. For administration of IPKC, such labeling would include amount, frequency and method of administration.

**Therapeutically Effective Dose**

Pharmaceutical compositions suitable for use in the present invention include compositions wherein the active ingredients are contained in an effective amount to achieve the intended purpose. The determination of an effective dose is well within the capability of those  
5 skilled in the art.

For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays, eg, of neoplastic cells, or in animal models, usually mice, rabbits, dogs, or pigs. The animal model is also used to achieve a desirable concentration range and route of administration. Such information can then be used to determine useful doses and routes for  
10 administration in humans.

A therapeutically effective dose refers to that amount of protein or its antibodies, antagonists, or inhibitors which ameliorate the symptoms or condition. Therapeutic efficacy and toxicity of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, eg, ED50 (the dose therapeutically effective in 50% of the  
15 population) and LD50 (the dose lethal to 50% of the population). The dose ratio between therapeutic and toxic effects is the therapeutic index, and it can be expressed as the ratio, ED50/LD50. Pharmaceutical compositions which exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies is used in formulating a range of dosage for human use. The dosage of such compounds lies preferably within a range of  
20 circulating concentrations that include the ED50 with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, sensitivity of the patient, and the route of administration.

The exact dosage is chosen by the individual physician in view of the patient to be treated. Dosage and administration are adjusted to provide sufficient levels of the active moiety  
25 or to maintain the desired effect. Additional factors which may be taken into account include the severity of the disease state, eg, tumor size and location; age, weight and gender of the patient; diet, time and frequency of administration, drug combination(s), reaction sensitivities, and tolerance/response to therapy. Long acting pharmaceutical compositions might be administered every 3 to 4 days, every week, or once every two weeks depending on half-life and clearance rate  
30 of the particular formulation.

Normal dosage amounts may vary from 0.1 to 100,000 micrograms, up to a total dose of about 1 g, depending upon the route of administration. Guidance as to particular dosages and

methods of delivery is provided in the literature. See US Patent Nos. 4,657,760; 5,206,344; or 5,225,212. Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.

5 It is contemplated, for example, that IPKC or an IPKC derivative can be delivered in a suitable formulation to prevent the induction of MDR in cancer cells. Such treatment would prevent the onset of drug resistant cancer cells and allow eradication of the cancer. Similarly, administration of agonists should also improve the activity or lifespan of this protein and lessen the onset and progression of various cancers.

10 The examples below are provided to illustrate the subject invention and are not included for the purpose of limiting the invention.

## INDUSTRIAL APPLICABILITY

### I cDNA LIBRARY CONSTRUCTIONS

The control human monocyte THP-1 cDNA library was custom constructed by Stratagene  
15 essentially as described. It was prepared by purifying poly(A+)RNA (mRNA) from THP-1 cells and then enzymatically synthesizing double stranded complementary DNA (cDNA) copies of the mRNA by priming with oligo d(T) or random hexamers and the two cDNA copies were treated separately. Synthetic adaptor oligonucleotides were ligated onto cDNA ends enabling its insertion into Uni-ZAP™ vector system (Stratagene), allowing high efficiency unidirectional  
20 (sense orientation) lambda library construction and the convenience of a plasmid system with blue/white color selection to detect clones with cDNA insertions. Finally, the two libraries were combined into a single library by mixing equal numbers of bacteriophage.

The PMA activated human monocyte THP-1 cDNA library was custom constructed by Stratagene (Stratagene, 11099 M. Torrey Pines Rd., La Jolla, CA 92037). Poly(A+)RNA  
25 (mRNA) was purified from THP-1 cells (cultured 48 hr with 100nm PMA diluted in DMSO). cDNA synthesis was primed separately with both oligo d(T) and random hexamers and the two cDNA copies were treated separately. Synthetic adaptor oligonucleotides were ligated onto cDNA ends enabling its insertion into Uni-ZAP™ vector system (Stratagene), allowing high efficiency unidirectional (sense orientation) lambda library construction and the convenience of a  
30 plasmid system with blue/white color selection to detect clones with cDNA insertions. Finally, the two libraries were combined into a single library by mixing equal numbers of bacteriophage.

The PMA and LPS activated human monocyte THP-1 cDNA library was custom

constructed by Stratagene (Stratagene, 11099 M. Torrey Pines Rd., La Jolla, CA 92037). Poly(A+)RNA (mRNA) was purified from THP-1 cells (cultured 48 hr with 100nm PMA in DMSO and for 4 hr activated with 1 $\mu$ g/ml LPS). cDNA synthesis was primed separately with both oligo d(T) and random hexamers and the two cDNA copies were treated separately.

5 Synthetic adaptor oligonucleotides were ligated onto cDNA ends enabling its insertion into Uni-ZAP™ vector system (Stratagene), allowing high efficiency unidirectional (sense orientation) lambda library construction and the convenience of a plasmid system with blue/white color selection to detect clones with cDNA insertions. Finally, the two libraries were combined into a single library by mixing equal numbers of bacteriophage.

10 The PMA induced THP-1, PMA and LPS induced THP-1, and control THP-1 cDNA libraries are screened with either DNA probes or antibody probes and the pBluescript® phagemid (Stratagene) can be rapidly excised in vivo. The phagemid allows the use of a plasmid system for easy insert characterization, sequencing, site-directed mutagenesis, the creation of unidirectional deletions and expression of fusion polypeptides. The custom-constructed library phage particles  
15 were transfected into E. coli host strain XL1-Blue® (Stratagene), which has a high transformation efficiency, increasing the probability of obtaining rare, under-represented clones in the cDNA library. Alternative unidirectional vectors include but are not limited to pcDNA1 (Invitrogen) and pSHlox-1 (Novagen).

## II ISOLATION OF cDNA CLONES

20 The phagemid forms of individual cDNA clones were obtained by the *in vivo* excision process, in which the host bacterial strain was coinfectd with both the lambda library phage and an f1 helper phage. Polypeptides derived from both the library-containing phage and the helper phage nicked the lambda DNA, initiated new DNA synthesis from defined sequences on the lambda target DNA and created a smaller, single stranded circular phagemid DNA molecule that  
25 included all DNA sequences of the pBluescript® plasmid and the cDNA insert. The phagemid DNA was secreted from the cells and purified, then used to re-infect fresh host cells, where the double stranded phagemid DNA was produced. Because the phagemid carries the gene for  $\beta$ -lactamase, the newly-transformed bacteria are selected on medium containing ampicillin.

Phagemid DNA was purified using the Magic Minipreps™ DNA Purification System  
30 (Promega catalogue #A7100. Promega Corp., 2800 Woods Hollow Rd., Madison, WI 53711). This small-scale process provides a simple and reliable method for lysing the bacterial cells and rapidly isolating purified phagemid DNA using a proprietary DNA-binding resin. The DNA was

eluted from the purification resin already prepared for DNA sequencing and other analytical manipulations.

Phagemid DNA was also purified using the QIAwell-8 Plasmid Purification System from QIAGEN®, QIAwell PLUS and QIAwell ULTRA DNA Purification System (QIAGEN Inc.,  
5 9259 Eton Ave., Chatsworth, CA 91311). This product line provides a convenient, rapid and reliable high-throughput method for lysing the bacterial cells and isolating highly purified phagemid DNA using QIAGEN anion-exchange resin particles with EMPORE™ membrane technology from 3M in a multiwell format. The DNA was eluted from the purification resin already prepared for DNA sequencing and other analytical manipulations.

### 10 III Homology Searching of cDNA Clones and Their Deduced Proteins

Each cDNA was compared to sequences in GenBank using a search algorithm developed by Applied Biosystems and incorporated into the INHERIT™ 670 Sequence Analysis System. In this algorithm, Pattern Specification Language (TRW Inc, Los Angeles CA) was used to determine regions of homology. The three parameters that determine how the sequence  
15 comparisons run were window size, window offset, and error tolerance. Using a combination of these three parameters, the DNA database was searched for sequences containing regions of homology to the query sequence, and the appropriate sequences were scored with an initial value. Subsequently, these homologous regions were examined using dot matrix homology plots to distinguish regions of homology from chance matches. Smith-Waterman alignments were used  
20 to display the results of the homology search.

Peptide and protein sequence homologies were ascertained using the INHERIT™ 670 Sequence Analysis System in a way similar to that used in DNA sequence homologies. Pattern Specification Language and parameter windows were used to search protein databases for sequences containing regions of homology which were scored with an initial value. Dot-matrix  
25 homology plots were examined to distinguish regions of significant homology from chance matches.

BLAST, which stands for Basic Local Alignment Search Tool (Altschul SF (1993) J Mol Evol 36:290-300; Altschul, SF et al (1990) J Mol Biol 215:403-10), was used to search for local sequence alignments. BLAST produces alignments of both nucleotide and amino acid sequences  
30 to determine sequence similarity. Because of the local nature of the alignments, BLAST is especially useful in determining exact matches or in identifying homologs. BLAST is useful for matches which do not contain gaps. The fundamental unit of BLAST algorithm output is the

### High-scoring Segment Pair (HSP).

An HSP consists of two sequence fragments of arbitrary but equal lengths whose alignment is locally maximal and for which the alignment score meets or exceeds a threshold or cutoff score set by the user. The BLAST approach is to look for HSPs between a query sequence and a database sequence, to evaluate the statistical significance of any matches found, and to report only those matches which satisfy the user-selected threshold of significance. The parameter E establishes the statistically significant threshold for reporting database sequence matches. E is interpreted as the upper bound of the expected frequency of chance occurrence of an HSP (or set of HSPs) within the context of the entire database search. Any database sequence whose match satisfies E is reported in the program output.

### IV Northern Analysis

Northern analysis is a laboratory technique used to detect the presence of a transcript of a gene which involves the hybridization of a labelled nucleotide sequence to a membrane on which RNAs from a particular cell type or tissue have been bound (Sambrook et al. supra). Northern analysis can be used to detect the presence of a transcript of the gene using a labelled nucleotide sequence.

Analogous computer techniques using BLAST (Altschul SF 1993 and 1990, supra) are used to search for identical or related molecules in nucleotide databases such as the GenBank or the LIFESEQ™ database (Incyte, Palo Alto CA). This analysis is much faster than multiple, membrane-based hybridizations. In addition, the sensitivity of the computer search can be modified to determine whether any particular match is categorized as exact or homologous.

The basis of the search is the product score which is defined as:

$$\frac{\% \text{ sequence identity} \times \% \text{ maximum BLAST score}}{100}$$

and it takes into account both the degree of similarity between two sequences and the length of the sequence match. For example, with a product score of 40, the match will be exact within a 1-2% error; and at 70, the match will be exact. Homologous molecules are usually identified by selecting those which show product scores between 15 and 40, although lower scores may identify related molecules.

### V Extension of IPKC to Full Length or to Recover Regulatory Elements

The nucleic acid sequence of full length IPKC (SEQ ID NO:1) is used to design oligonucleotide primers for extending a partial nucleotide sequence to full length or for obtaining

5' sequences from genomic libraries. One primer is synthesized to initiate extension in the antisense direction (XLR) and the other is synthesized to extend sequence in the sense direction (XLF). Primers allow the extension of the known IPKC sequence "outward" generating amplicons containing new, unknown nucleotide sequence for the region of interest (US Patent 5 Application 08/487,112, filed 6/7/1995, specifically incorporated by reference). The initial primers are designed from the cDNA using OLIGO<sup>®</sup> 4.06 Primer Analysis Software (National Biosciences), or another appropriate program, to be 22-30 nucleotides in length, to have a GC content of 50% or more, and to anneal to the target sequence at temperatures about 68°-72° C. Any stretch of nucleotides which would result in hairpin structures and primer-primer dimerizations is avoided.

The original, selected cDNA libraries, or a human genomic library are used to extend the sequence; the latter is most useful to obtain 5' upstream regions. If more extension is necessary or desired, additional sets of primers are designed to further extend the known region.

By following the instructions for the XL-PCR kit (Perkin Elmer) and thoroughly mixing the enzyme and reaction mix, high fidelity amplification is obtained. Beginning with 40 pmol of each primer and the recommended concentrations of all other components of the kit, PCR is performed using the Peltier Thermal Cycler (PTC200; MJ Research, Watertown MA) and the following parameters:

20	Step 1	94° C for 1 min (initial denaturation)
	Step 2	65° C for 1 min
	Step 3	68° C for 6 min
	Step 4	94° C for 15 sec
	Step 5	65° C for 1 min
	Step 6	68° C for 7 min
25	Step 7	Repeat step 4-6 for 15 additional cycles
	Step 8	94° C for 15 sec
	Step 9	65° C for 1 min
	Step 10	68° C for 7:15 min
	Step 11	Repeat step 8-10 for 12 cycles
30	Step 12	72° C for 8 min
	Step 13	4° C (and holding)

A 5-10  $\mu$ l aliquot of the reaction mixture is analyzed by electrophoresis on a low concentration (about 0.6-0.8%) agarose mini-gel to determine which reactions were successful in extending the sequence. Bands thought to contain the largest products were selected and cut out of the gel. Further purification involves using a commercial gel extraction method such as QIAQuick<sup>™</sup> (QIAGEN Inc). After recovery of the DNA, Klenow enzyme was used to trim

single-stranded, nucleotide overhangs creating blunt ends which facilitate religation and cloning.

After ethanol precipitation, the products are redissolved in 13  $\mu$ l of ligation buffer, 1  $\mu$ l T4-DNA ligase (15 units) and 1  $\mu$ l T4 polynucleotide kinase are added, and the mixture is incubated at room temperature for 2-3 hours or overnight at 16° C. Competent *E. coli* cells (in 5 40  $\mu$ l of appropriate media) are transformed with 3  $\mu$ l of ligation mixture and cultured in 80  $\mu$ l of SOC medium (Sambrook J et al, supra). After incubation for one hour at 37° C, the whole transformation mixture is plated on Luria Bertani (LB)-agar (Sambrook J et al, supra) containing 2xCarb. The following day, several colonies are randomly picked from each plate and cultured in 150  $\mu$ l of liquid LB/2xCarb medium placed in an individual well of an appropriate, 10 commercially-available, sterile 96-well microtiter plate. The following day, 5  $\mu$ l of each overnight culture is transferred into a non-sterile 96-well plate and after dilution 1:10 with water, 5  $\mu$ l of each sample is transferred into a PCR array.

For PCR amplification, 18  $\mu$ l of concentrated PCR reaction mix (3.3x) containing 4 units of rTth DNA polymerase, a vector primer and one or both of the gene specific primers used for 15 the extension reaction are added to each well. Amplification is performed using the following conditions:

20	Step 1	94° C for 60 sec
	Step 2	94° C for 20 sec
	Step 3	55° C for 30 sec
	Step 4	72° C for 90 sec
	Step 5	Repeat steps 2-4 for an additional 29 cycles
	Step 6	72° C for 180 sec
	Step 7	4° C (and holding)

Aliquots of the PCR reactions are run on agarose gels together with molecular weight 25 markers. The sizes of the PCR products are compared to the original partial cDNAs, and appropriate clones are selected, ligated into plasmid and sequenced.

## VI Labeling and Use of Hybridization Probes

Hybridization probes derived from SEQ ID NO:1 are employed to screen cDNAs, genomic DNAs or mRNAs. Although the labeling of oligonucleotides, consisting of about 20 30 base-pairs, is specifically described, essentially the same procedure is used with larger cDNA fragments. Oligonucleotides are designed using state-of-the-art software such as OLIGO 4.06 (National Biosciences), labeled by combining 50 pmol of each oligomer and 250 mCi of [ $\gamma$ -<sup>32</sup>P] adenosine triphosphate (Amersham, Chicago IL) and T4 polynucleotide kinase (DuPont NEN®, Boston MA). The labeled oligonucleotides are purified with Sephadex G-25 super fine resin



column (Pharmacia). A portion containing  $10^7$  counts per minute of each of the sense and antisense oligonucleotides is used in a typical membrane based hybridization analysis of human genomic DNA digested with one of the following endonucleases (Ase I, Bgl II, Eco RI, Pst I, Xba I, or Pvu II; DuPont NEN®).

- 5           The DNA from each digest is fractionated on a 0.7 percent agarose gel and transferred to nylon membranes (Nytran Plus, Schleicher & Schuell, Durham NH). Hybridization is carried out for 16 hours at 40°C. To remove nonspecific signals, blots are sequentially washed at room temperature under increasingly stringent conditions up to 0.1 x saline sodium citrate and 0.5% sodium dodecyl sulfate. After XOMAT AR™ film (Kodak, Rochester NY) is exposed to the  
10 blots in a Phosphorimager cassette (Molecular Dynamics, Sunnyvale CA) for several hours, hybridization patterns are compared visually.

#### VII    Antisense Molecules

- The ipkc sequence, or any part thereof, is used to inhibit in vivo or in vitro expression of naturally occurring ipkc. Although use of antisense oligonucleotides, comprising about 20 base-  
15 pairs, is specifically described, essentially the same procedure is used with larger cDNA fragments. An oligonucleotide based on the coding sequence of IPKC as shown in Figures 1A and 1B is used to inhibit expression of naturally occurring IPKC. The complementary oligonucleotide is designed from the most unique 5' sequence as shown in Figures 1A and 1B and used either to inhibit transcription by preventing promoter binding to the upstream nontranslated  
20 sequence or translation of an ipkc transcript by preventing the ribosome from binding. Using an appropriate portion of the leader and 5' sequence of SEQ ID NO:1, an effective antisense oligonucleotide includes any 15-20 nucleotides spanning the region which translates into the signal or early coding sequence of the polypeptide as shown in Figures 1A and 1B.

#### VIII   Expression of IPKC

- 25           Expression of the IPKC is accomplished by subcloning the cDNAs into appropriate vectors and transfecting the vectors into host cells. In this case, the cloning vector, pSport, previously used for the generation of the cDNA library is used to express IPKC in E. coli. Upstream of the cloning site, this vector contains a promoter for  $\beta$ -galactosidase, followed by sequence containing the amino-terminal Met and the subsequent 7 residues of  $\beta$ -galactosidase.  
30 Immediately following these eight residues is a bacteriophage promoter useful for transcription and a linker containing a number of unique restriction sites.

          Induction of an isolated, transfected bacterial strain with IPTG using standard methods

produces a fusion protein which consists of the first seven residues of  $\beta$ -galactosidase, about 5 to 15 residues of linker, and the full length IPKC. The signal sequence directs the secretion of IPKC into the bacterial growth media which can be used directly in the following assay for activity.

## 5 IX IPKC Activity

IPKC activity can be assayed by measuring PKC activity. PKC activity is found by measuring the transfer of radioactivity from [ $\gamma$ - $^{32}\text{P}$ ]-ATP to a protein substrate, such as histone type III, myelin basic protein, or EGF receptor peptide (Kennelly PJ et al (1991) J Biol Chem 266: 15555-15558). The reaction conditions (addition of  $\text{Ca}^{+2}$ , phospholipid, phorbol  
10 ester, etc) are adjusted to the isoform of PKC used. IPKC is added to the reaction mixture prior to the addition of substrate. The effect on PKC activity is measured at many dosages of IPKC and compared to a sample lacking IPKC.

## X Production of IPKC Specific Antibodies

IPKC purified using PAGE electrophoresis (Sambrook, supra) is used to immunize  
15 rabbits and to produce antibodies using standard protocols. The amino acid sequence translated from IPKC is analyzed using DNASTar software (DNASTar Inc) to determine regions of high immunogenicity and a corresponding oligopolypeptide is synthesized and used to raise antibodies by means known to those of skill in the art. Analysis to select appropriate epitopes, such as those near the C-terminus or in hydrophilic regions is described by Ausubel FM et al (supra) and  
20 shown in Figures 5 and 6.

Typically, the oligopeptides are 15 residues in length, synthesized using an Applied Biosystems Peptide Synthesizer Model 431A using fmoc-chemistry, and coupled to keyhole limpet hemocyanin (KLH, Sigma) by reaction with M-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS; Ausubel FM et al, supra). Rabbits are immunized with the oligopeptide-KLH  
25 complex in complete Freund's adjuvant. The resulting antisera are tested for antipeptide activity, for example, by binding the peptide to plastic, blocking with 1% BSA, reacting with rabbit antisera, washing, and reacting with radioiodinated, goat anti-rabbit IgG.

## XI Purification of Naturally Occurring IPKC Using Specific Antibodies

Naturally occurring or recombinant IPKC is purified by immunoaffinity chromatography  
30 using antibodies specific for IPKC. An immunoaffinity column is constructed by covalently coupling IPKC antibody to an activated chromatographic resin such as CnBr-activated Sepharose (Pharmacia Biotech). After the coupling, the resin is blocked and washed according to the

manufacturer's instructions.

Media containing IPKC is passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of IPKC (eg, high ionic strength buffers in the presence of detergent). The column is eluted under conditions that disrupt  
5 antibody/IPKC binding (eg, a buffer of pH 2-3 or a high concentration of a chaotrope such as urea or thiocyanate ion), and IPKC is collected.

## **XII Identification of Molecules Which Interact with IPKC**

IPKC, or biologically active fragments thereof, are labelled with  $^{125}\text{I}$  Bolton-Hunter reagent (Bolton, AE and Hunter, WM (1973) Biochem J 133: 529). Candidate molecules  
10 previously arrayed in the wells of a 96 well plate are incubated with the labelled IPKC, washed and any wells with labelled IPKC complex are assayed. Data obtained using different concentrations of IPKC are used to calculate values for the number, affinity, and association of IPKC with the candidate molecules.

All publications and patents mentioned in the above specification are herein incorporated  
15 by reference. Various modifications and variations of the described method and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying  
20 out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims.

## SEQUENCE LISTING

## (1) GENERAL INFORMATION

(i) APPLICANT: INCYTE PHARMACEUTICALS, INC.

(ii) TITLE OF THE INVENTION: HUMAN PROTEIN KINASE C INHIBITOR  
HOMOLOG

(iii) NUMBER OF SEQUENCES: 10

## (iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Incyte Pharmaceuticals, Inc.  
(B) STREET: 3174 Porter Drive  
(C) CITY: Palo Alto  
(D) STATE: CA  
(E) COUNTRY: U.S.  
(F) ZIP: 94304

## (v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Diskette  
(B) COMPUTER: IBM Compatible  
(C) OPERATING SYSTEM: DOS  
(D) SOFTWARE: FastSEQ Version 1.5

## (vi) CURRENT APPLICATION DATA:

(A) PCT APPLICATION NUMBER: To Be Assigned  
(B) FILING DATE: Herewith

## (vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: US 08/666,798  
(B) FILING DATE: 18-JUN-1996

## (viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Billings, Lucy J.  
(B) REGISTRATION NUMBER: 36,749  
(C) REFERENCE/DOCKET NUMBER: PF-0080 PCT

## (ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: 415-855-0555  
(B) TELEFAX: 415-845-4166

## (2) INFORMATION FOR SEQ ID NO:1:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 640 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: cDNA

## (vii) IMMEDIATE SOURCE:

(A) LIBRARY: CONSENSUS

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

TACGACTCAC	TGTAGGGAAA	GCTGGTACGC	CTGCAGGGGG	CTCGCCCGGC	CGCCACTACC	60
CCGCTTCCCC	GAGCCCGGAG	TCCCCACCCA	CGGCCGGCCG	AGGAGCCGAG	TGCTGACCCG	120
GGTGAGAGGT	TCCCGCGGCT	CAGGGAAGAT	GGCGGCAGCG	TGGTGCTGGC	TGCTGGGTTG	180
CGCGCGGCGC	GCAGAGCCGT	GGCGGCCACG	GGGGTGCGCG	GGGGGCAGGT	CCGAGGAGCT	240
GCAGGTGTGA	CTGATGAGGA	ATGAAGTGCC	CAAGGCCCAG	CAGGCAACTC	CTGGGGGAGC	300

AGCCCCAACC	ATCTTCTCCC	GGATCCTGGA	CAAGAGCCTC	CCAGCTGACA	TTCTCTATGA	360
GGACCAGCAG	TGTCTTGTGT	TCCGTGATGT	GGCCCCTCAG	GCTCCTGTGC	ACTTCCTGGT	420
CATTCCCTAAG	AAGCCCATTTC	CTCGGATTAG	CCAGGCTGAA	GAAGAAGACC	AGCAGCTTCT	480
AGGACACCTA	CTCCTTGTGG	CCAAGCAGAC	AGCAAAGGCT	GAGGGCCTGG	GAGATGGATA	540
CCGACTTGTG	ATCAACGATG	GGAAGCTGGG	TGCACAATCT	GTGTATCATC	TGCACATTCA	600
TGTACTTGGG	GGCCGGCAGC	TCCAGTGGCC	TCCAGTTGA			640

## (2) INFORMATION FOR SEQ ID NO:2:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 128 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: peptide

## (vii) IMMEDIATE SOURCE:

- (A) LIBRARY: CONSENSUS

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met	Arg	Asn	Glu	Val	Ala	Lys	Ala	Gln	Gln	Ala	Thr	Pro	Gly	Gly	Ala
1				5				10					15		
Ala	Pro	Thr	Ile	Phe	Ser	Arg	Ile	Leu	Asp	Lys	Ser	Leu	Pro	Ala	Asp
			20					25				30			
Ile	Leu	Tyr	Glu	Asp	Gln	Gln	Cys	Leu	Val	Phe	Arg	Asp	Val	Ala	Pro
		35				40						45			
Gln	Ala	Pro	Val	His	Phe	Leu	Val	Ile	Pro	Lys	Lys	Pro	Ile	Pro	Arg
	50				55					60					
Ile	Ser	Gln	Ala	Glu	Glu	Asp	Gln	Gln	Leu	Leu	Gly	His	Leu	Leu	
65				70				75				80			
Leu	Val	Ala	Lys	Gln	Thr	Ala	Lys	Ala	Glu	Gly	Leu	Gly	Asp	Gly	Tyr
			85					90				95			
Arg	Leu	Val	Ile	Asn	Asp	Gly	Lys	Leu	Gly	Ala	Gln	Ser	Val	Tyr	His
			100				105					110			
Leu	His	Ile	His	Val	Leu	Gly	Gly	Arg	Gln	Leu	Gln	Trp	Pro	Pro	Gly
		115				120						125			

## (2) INFORMATION FOR SEQ ID NO:3:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 233 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: cDNA

## (vii) IMMEDIATE SOURCE:

- (A) LIBRARY: BRSTNOT03
- (B) CLONE: 1004126

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

ACCCACGGCC	GGCCGCGGAG	CCGAGTGCTG	ACCCGGGTGA	GAGGTTCCCG	CGGCTCAGGG	60
AAGATGGCGG	CAGCGTGGTG	CTGGCTGCTG	GGTTGCGCGC	GGCGCGCAGA	GCCGTGGCGG	120
CCACGGGGGT	GCGCGGGGGG	CAGTCCGAG	GAGCTGCAGG	TGTGACTGAT	GGAATGAAG	180
TGGCCAAGGC	CCAGCAGGCA	ACTCTGGGG	GAGCAGCCCC	AACCATCTTC	TNC	233

## (2) INFORMATION FOR SEQ ID NO:4:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 254 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: cDNA

## (vii) IMMEDIATE SOURCE:

- (A) LIBRARY: HNT2AGT01
- (B) CLONE: 488082

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

AGAGGTTCCC	GCGGCTCAGG	GAAGATGGCG	GCAGCGTGGT	GCTGGCTGCT	GGGTTGCGCG	60
CGGCGCGCAG	AGCCGTGGCG	GCCACGGGGG	TGCGCGGGGG	GCAGGTCCGA	GGAGCTGCAG	120
GTGTGACTGA	TGGGAATGAA	GTGGCCAAGG	CCCAGCAGGC	AACTCCTGGG	GGAGCAGCCC	180
CAACCATCTT	CTCCCGGATC	CTGGACAAGA	GCCTNCCAGC	TGACATTCTC	TATGAGGACC	240
AGCAGTGTCT	TGTT					254

## (2) INFORMATION FOR SEQ ID NO:5:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 279 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: cDNA

## (vii) IMMEDIATE SOURCE:

- (A) LIBRARY: BRSTTUT03
- (B) CLONE: 899728

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

GGCCCAGCAG	GCAACTCCTG	GGGGAGCAGC	CCCAACCATC	TTCTCCCGGA	TCCTGGACAA	60
GAGCCTCCCA	GCTGACATTC	TCTATGAGGA	CCAGCAGTGT	CTTGTGTTCC	GTGATGTGGC	120
CCCTCAGGCT	CCTGTGCACT	TCCTGGTCAT	TCCTAAGAAG	CCCATTCTCT	GGATTAGCCA	180
GGCTGAAGAA	GAAGACCAGC	AGGTGGGAAG	AACAGGGCCA	GGGTTTGGCT	GGGAGGAGCC	240
CCTGGACCCA	GCTAGAGGTC	TTGCTCCCTA	TGAATGAGG			279

## (2) INFORMATION FOR SEQ ID NO:6:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 242 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: cDNA

## (vii) IMMEDIATE SOURCE:

- (A) LIBRARY: PGANNOT01
- (B) CLONE: 625024

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

CCCCAGCAGG	CAACTCCTGG	GGGAGCAGCC	CCAACCATCT	TCTNCCGGAT	CCTGGACAAG	60
AGCCTCCCAG	CTGACATTCT	CTATGAGGAC	CAGCAGTGTC	TTGTGTTCCG	TGATGTGGCC	120
CCTCAGGCTC	CTGTGCACTT	CCTGGTCATT	CCTAAGAAGC	CCATTCTCTG	GATTAGCCAG	180

GNTGAAGAAG AAGACCAGCA GCTTCTAGGA CANCTACTNC TTGTGGCCAA GCAGACAGCA 240  
AA 242

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 232 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vii) IMMEDIATE SOURCE:

- (A) LIBRARY: THP1PEB01
- (B) CLONE: 075682

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

AGTGGNCAAG GCCCAGCAGG CAACTCCTGG GGGAGCAGCC CCAACCATCT TCTCCCGGTT 60  
CCTGGACAAG AGCCTCCAG CTGACATTNT CTATGAGGAC CAGCAGTGTC TTGTGTTCCG 120  
TGATGTGGCC CCTNAGGCTC CTGTGCACTT CCTGGTCATT CCTAAGAAGN CCATTNCTCG 180  
GATTAGNCAG GCTGAAGANG ANGACCAGCA GCTTNTAGGN CACCTACTCC TT 232

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 126 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(vii) IMMEDIATE SOURCE:

- (A) LIBRARY: GenBank
- (B) CLONE: 493051

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

Met	Ala	Asp	Glu	Ile	Ala	Lys	Ala	Gln	Val	Ala	Arg	Pro	Gly	Gly	Asp	1	5	10	15
Thr	Ile	Phe	Gly	Lys	Ile	Ile	Arg	Lys	Glu	Ile	Pro	Ala	Lys	Ile	Ile	20	25	30	
Tyr	Glu	Asp	Asp	Gln	Cys	Leu	Ala	Phe	His	Asp	Ile	Ser	Pro	Gln	Ala	35	40	45	
Pro	Thr	His	Phe	Leu	Val	Ile	Pro	Lys	Lys	Tyr	Ile	Ser	Gln	Ile	Ser	50	55	60	
Ala	Ala	Glu	Asp	Asp	Asp	Glu	Ser	Leu	Leu	Gly	His	Leu	Met	Ile	Val	65	70	75	80
Gly	Lys	Lys	Cys	Ala	Ala	Asp	Leu	Gly	Leu	Lys	Lys	Gly	Tyr	Arg	Met	85	90	95	
Val	Val	Asn	Glu	Gly	Ser	Asp	Gly	Gly	Gln	Ser	Val	Tyr	His	Val	His	100	105	110	
Leu	His	Val	Leu	Gly	Gly	Arg	Gln	Met	Asn	Trp	Pro	Pro	Gly			115	120	125	

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 126 amino acids

(B) TYPE: amino acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(vii) IMMEDIATE SOURCE:

(A) LIBRARY: GenBank  
 (B) CLONE: 862933

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

Met	Ala	Asp	Glu	Ile	Ala	Lys	Ala	Gln	Val	Ala	Arg	Pro	Gly	Gly	Asp
1				5					10					15	
Thr	Ile	Phe	Gly	Lys	Ile	Ile	Arg	Lys	Glu	Ile	Pro	Ala	Lys	Ile	Ile
			20					25					30		
Phe	Glu	Asp	Asp	Arg	Cys	Leu	Ala	Phe	His	Asp	Ile	Ser	Pro	Gln	Ala
		35					40					45			
Pro	Thr	His	Phe	Leu	Val	Ile	Pro	Lys	Lys	His	Ile	Ser	Gln	Ile	Ser
		50				55					60				
Val	Ala	Glu	Asp	Asp	Asp	Glu	Ser	Leu	Leu	Gly	His	Leu	Met	Ile	Val
65					70					75				80	
Gly	Lys	Lys	Cys	Ala	Ala	Asp	Leu	Gly	Leu	Asn	Lys	Gly	Tyr	Arg	Met
			85						90					95	
Val	Val	Asn	Glu	Gly	Ser	Asp	Gly	Gly	Gln	Ser	Val	Tyr	His	Val	His
			100					105					110		
Leu	His	Val	Leu	Gly	Gly	Arg	Gln	Met	His	Trp	Pro	Pro	Gly		
		115					120						125		

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 126 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(vii) IMMEDIATE SOURCE:

(A) LIBRARY: GenBank  
 (B) CLONE: 493050

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

Met	Ala	Asp	Glu	Ile	Ala	Lys	Ala	Gln	Val	Ala	Arg	Pro	Gly	Gly	Asp
1				5					10					15	
Thr	Ile	Phe	Gly	Lys	Ile	Ile	Arg	Lys	Glu	Ile	Pro	Ala	Lys	Ile	Ile
			20					25					30		
Tyr	Glu	Asp	Asp	Gln	Cys	Leu	Ala	Phe	His	Asp	Ile	Ser	Pro	Gln	Ala
		35					40					45			
Pro	Thr	His	Phe	Leu	Val	Ile	Pro	Lys	Lys	Tyr	Ile	Ser	Gln	Ile	Ser
		50				55					60				
Ala	Ala	Glu	Asp	Asp	Asp	Glu	Ser	Leu	Leu	Gly	His	Leu	Met	Ile	Val
65					70					75				80	
Gly	Lys	Lys	Cys	Ala	Ala	Asp	Leu	Gly	Leu	Lys	Lys	Gly	Tyr	Arg	Met
			85						90					95	
Val	Val	Asn	Glu	Gly	Ser	Asp	Gly	Gly	Gln	Ser	Val	Tyr	His	Val	His
			100					105					110		
Leu	His	Val	Leu	Gly	Gly	Arg	Gln	Met	Asn	Trp	Pro	Pro	Gly		
		115					120						125		



## CLAIMS

1. A purified polynucleotide encoding a polypeptide having an amino acid sequence shown in SEQ ID NO:2.
2. The polynucleotide of Claim 1 wherein the nucleic acid sequence comprises SEQ ID NO:1, or its complement.
3. A diagnostic test for conditions or diseases associated with expression of protein kinase C inhibitor homolog (ipkc) in a biological sample comprising the steps of:
  - a) combining the biological sample with the polynucleotide of Claim 1, or a fragment thereof, under conditions suitable for the formation of hybridization complex; and
  - 10 b) detecting the hybridization complex, wherein the presence of the complex correlates with expression of the polynucleotide of Claim 1 in the biological sample.
4. An expression vector comprising the polynucleotide of Claim 1.
5. A host cell transformed with the expression vector of Claim 4.
6. A method for producing a polypeptide comprising the amino acid sequence shown in SEQ ID NO:2, the method comprising the steps of:
  - a) culturing the host cell of Claim 5 under conditions suitable for the expression of the polypeptide; and
  - b) recovering the polypeptide from the host cell culture.
7. An antisense molecule comprising the nucleic acid sequence complementary to at least a portion of the polynucleotide of Claim 1.
8. A pharmaceutical composition comprising the antisense molecule of Claim 7 and a pharmaceutically acceptable excipient.
9. A method of treating a subject with a condition or disease associated with the expression of human protein kinase C inhibitor homolog comprising administering an effective amount of the pharmaceutical composition of Claim 8 to the subject.
10. A purified polypeptide comprising the amino acid sequence of SEQ ID NO:2.
11. A pharmaceutical composition comprising the polypeptide of Claim 10 and a pharmaceutically acceptable excipient.
12. A method of treating a subject with a condition or disease associated with the expression of human protein kinase C comprising administering an effective amount of the pharmaceutical composition of Claim 11 to the subject.
13. An agonist of the polypeptide of Claim 10.

14. A pharmaceutical composition comprising the agonist of Claim 13 and a pharmaceutically acceptable excipient.
15. A method of treating a subject with a condition or disease associated with the expression of human protein kinase C inhibitor homolog comprising administering an effective  
5 amount of the pharmaceutical composition of Claim 14 to the subject.
16. An antibody specific for the purified polypeptide of Claim 10.
17. A diagnostic test for a condition or disease associated with the expression of protein kinase C inhibitor in a biological sample comprising the steps of:
  - a) combining the biological sample with the antibody of Claim 16, under  
10 conditions suitable for the antibody to bind the polypeptide and form an antibody:polypeptide complex; and
  - b) detecting the complex, wherein the presence of the complex correlates with the expression of the polypeptide in the biological sample.
18. A pharmaceutical composition comprising the antibody of Claim 16 and a  
15 pharmaceutically acceptable excipient.
19. A method of treating a subject with a condition or disease associated with the expression of human protein kinase C inhibitor homolog comprising administering an effective amount of the pharmaceutical composition of Claim 18 to the subject.
20. An inhibitor of the polypeptide of Claim 10.

1/7

```

          9      18      27      36      45      54
5' NNT ACG ACT CAC TGT AGG GAA AGC TGG TAC GCG TGC AGG GGG CTC GCC CGG CCG

          63      72      81      90      99      108
CCA CTA CCC CGC TTC CCC GAG CCC GGA GTC CCC ACC CAC GGC CGG CCG AGG AGC

          117     126     135     144     153     162
CGA GTG CTG ACC CGG GTG AGA GGT TCC CGC GGC TCA GGG AAG ATG GCG GCA GCG

          171     180     189     198     207     216
TGG TGC TGG CTG CTG GGT TGC GCG CGG CGC GCA GAG CCG TGG CGG CCA CGG GGG

          225     234     243     252     261     270
TGC GCG GGG GGC AGG TCC GAG GAG CTG CAG GTG TGA CTG ATG AGG AAT GAA GTG
                                     M R N E V

          279     288     297     306     315     324
GCC AAG GCC CAG CAG ACT CCT GGG GGA GCA GCC CCA ACC ATC TTC TCC CGG
A K A Q Q A T P G G A A P T I F S R

          333     342     351     360     369     378
ATC CTG GAC AAG AGC CTC CCA GCT GAC ATT CTC TAT GAG GAC CAG CAG TGT CTT
I L D K S L P A D I L Y E D Q Q C L

```

FIGURE 1A

2/7

387	GTG TTC CGT GAT GTG GCC CCT CAG GCT CCT GTG CAC TTC CTG GTC ATT CCT AAG	432
	V F R D V A A P Q A P V H F L V I P K	
441	AAG CCC ATT CCT CGG ATT AGC CAG GCT GAA GAA GAC CAG CAG CTT CTA GGA	486
	K P I P R I S Q A E E E D Q Q L L G	
495	CAC CTA CTC CTT GTG GCC AAG CAG ACA GCA AAG GCT GAG GGC CTG GGA GAT GGA	540
	H L L L V A K Q T A K A E G L G D G	
549	TAC CGA CTT GTG ATC AAC GAT GGG AAG CTG GGT GCA CAA TCT GTG TAT CAT CTG	594
	Y R L V I N D G K L G A Q S V Y H L	
603	CAC ATT CAT GTA CTT GGG GGC CGG CAG CTC CAG TGG CCT CCA GGT TGA 3'	639
	H I H V L G G R Q L Q W P P G	

FIGURE 1B




FIGURE 2

4/7

The Electronic Northern for Clone: 075682  
and Stringency = 50

Library	Lib Description
THP1PEB01	THP-1 promonocyte cell line, treated PMA
CRBLNOT01	brain, cerebellum, 69 M
SCORNOT01	spinal cord, 71 M
HNT2AGT01	hNT-2 cell line, post-mitotic neurons
PGANNOT01	brain, paraganglia, 46 M
BRAITUT03	brain tumor, astrocytoma, 17 F
BRSTTUT03	breast tumor, 58 F, match to BRSTNOT05
BRSTNOT03	breast, 54 F, match to BRSTTUT02
PLACNOM02	placenta, neonatal F, NORM, WM
LIVSFEM02	liver/spleen, fetal M, NORM, WM

FIGURE 3

1	M	R	N	E	V	A	K	A	Q	Q	A	T	P	G	G	A	A	P	T	I	F	S	R	I	L	D	K	S	L	P	A	D	I	L	Y	E	D	Q	Q	C	IPKC
1	M	A	D	E	I	A	K	A	Q	V	A	R	P	G	G	D	-	-	T	I	F	G	K	I	I	R	K	E	I	P	A	K	I	I	Y	E	D	D	Q	C	GI 493051
1	M	A	D	E	I	A	K	A	Q	V	A	R	P	G	G	D	-	-	T	I	F	G	K	I	I	R	K	E	I	P	A	K	I	I	F	E	D	D	R	C	GI 862933
1	M	A	D	E	I	A	K	A	Q	V	A	R	P	G	G	D	-	-	T	I	F	G	K	I	I	R	K	E	I	P	A	K	I	I	Y	E	D	D	Q	C	GI 493050
41	L	V	F	R	D	V	A	P	Q	A	P	V	H	F	L	V	I	P	K	K	P	I	P	R	I	S	Q	A	E	E	D	Q	Q	L	L	G	H	L	L	IPKC	
39	L	A	F	H	D	I	S	P	Q	A	P	T	H	F	L	V	I	P	K	K	Y	I	S	Q	I	S	A	A	E	D	D	D	E	S	L	L	G	H	L	M	GI 493051
39	L	A	F	H	D	I	S	P	Q	A	P	T	H	F	L	V	I	P	K	K	H	I	S	Q	I	S	V	A	E	D	D	D	E	S	L	L	G	H	L	M	GI 862933
39	L	A	F	H	D	I	S	P	Q	A	P	T	H	F	L	V	I	P	K	K	Y	I	S	Q	I	S	A	A	E	D	D	D	E	S	L	L	G	H	L	M	GI 493050
81	L	V	A	K	Q	T	A	K	A	E	G	L	G	D	G	Y	R	L	V	I	N	D	G	K	L	G	A	Q	S	V	Y	H	L	H	V	L	G	G	IPKC		
79	I	V	G	K	K	C	A	A	D	L	G	L	K	K	G	Y	R	M	V	V	N	E	G	S	D	G	G	Q	S	V	Y	H	V	H	L	H	V	L	G	GI 493051	
79	I	V	G	K	K	C	A	A	D	L	G	L	N	K	G	Y	R	M	V	V	N	E	G	S	D	G	G	Q	S	V	Y	H	V	H	L	H	V	L	G	GI 862933	
79	I	V	G	K	K	C	A	A	D	L	G	L	K	K	G	Y	R	M	V	V	N	E	G	S	D	G	G	Q	S	V	Y	H	V	H	L	H	V	L	G	GI 493050	
121	R	Q	L	Q	W	P	P	P	G																														IPKC		
119	R	Q	M	N	W	P	P	P	G																													GI 493051			
119	R	Q	M	H	W	P	P	P	G																													GI 862933			
119	R	O	M	N	W	P	P	P	G																													GI 493050			

FIGURE 4

6/7




FIGURE 5



7/7




FIGURE 6

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 97/10598

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/12 C12N15/74 C07K14/47 C07K16/18 C12N9/12  
C12N1/21 C12Q1/68 G01N33/50 G01N33/53 A61K38/17  
A61K39/00 A61K48/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07K C12N G01N A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	HILLIER, L., ET AL. : "THE WASHU-MERCK EST-PROJECT" EMBL SEQUENCE DATA LIBRARY, 16 June 1996, HEIDELBERG, GERMANY, XP002043833	1
Y	ACCESSION NO. W67311	4-6, 10-12
Y	--- LIMA, C.D., ET AL. : "THREE-DIMENSIONAL STRUCTURE OF HUMAN PROTEIN KINASE C INTERACTING PROTEIN 1, A MEMBER OF THE HIT FAMILY OF PROTEINS" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE USA, vol. 93, May 1996, pages 5357-5362, XP002043834 see the whole document --- -/-	4-6,10

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

16 October 1997

Date of mailing of the international search report

04. 11. 97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 eponl,  
Fax: (+31-70) 340-3016

Authorized officer

Holtorf, S

## INTERNATIONAL SEARCH REPORT

Intern: at Application No

PCT/US 97/10598

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>DATABASE WPI  Section Ch, Week 9338  Derwent Publications Ltd., London, GB;  Class B04, AN 93-299558  XP002043839  &amp; JP 05 213 769 A (KOWA CO LTD) , 24  August 1993  see abstract</p> <p>---</p>	4-6, 10-12
Y	<p>WO 93 20101 A (GLAXO S A ; DIAZ MECO CONDE  MARIE TERESA (ES); MOSCAT GUILLEN JORGE)  14 October 1993  pages 2,7,8</p> <p>---</p>	10-12
A	<p>PEARSON, J.D., ET AL. : "AMINO ACID  SEQUENCE AND CHARACTERIZATION OF A PROTEIN  INHIBITOR OF PROTEIN KINASE C"  THE JOURNAL OF BIOLOGICAL CHEMISTRY,  vol. 265, no. 8, March 1990,  pages 4583-4591, XP002043835  cited in the application  see the whole document</p> <p>---</p>	1-20
A	<p>BRZOSKA, P.M., ET AL. : "THE PRODUCT OF  THE ATAXIA-TELANGIECTASIA GROUP D  COMPLEMENTING GENE, ATDC, INTERACTS WITH A  PROTEIN KINASE C SUBSTRATE AND INHIBITOR"  PROCEEDINGS OF THE NATIONAL ACADEMY OF  SCIENCES OF THE USA,  vol. 92, August 1995,  pages 7824-7828, XP002043836  cited in the application  see the whole document</p> <p>---</p>	1-20
A	<p>WO 94 14798 A (GOEDECKE AG ; TROSTMANN UWE  (DE); HARTENSTEIN JOHANNES (DE); BARTH) 7  July 1994  see the whole document</p> <p>---</p>	1-20
A	<p>CHEN, C-Y. AND FALLER, D.V.:  "PHOSPHORYLATION OF Bcl-2 PROTEIN AND  ASSOCIATION WITH p21ras IN RAS-INDUCED  APOPTOSIS"  THE JOURNAL OF BIOLOGICAL CHEMISTRY,  vol. 271, no. 5, February 1996,  pages 2376-2379, XP002043837  see the whole document</p> <p>---</p>	1-20
	---	

-/--

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 97/10598

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	BRZOSKA, P.M., ETAL . : "CLONING,MAPPING, AND in vivo LOCALIZATION OF A HUMAN MEMBER OF THE PKCI-1 PROTEIN FAMILY (PRKCNH1)" GENOMICS, vol. 36, no. 1, August 1996, pages 151-156, XP002043838	16,17
P,Y	SEE PAGE 153, LEFT COLUMN, PAGE 155, LEFT COLUMN  -----	4-6

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 97/ 10598

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claims 3,17 are directed to a diagnostic method practised on the human/animal body and claims 9,12,15,19 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 97/10598

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9320101 A	14-10-93	EP 0592634 A JP 6508154 T	20-04-94 14-09-94
WO 9414798 A	07-07-94	DE 4243321 A AU 5813794 A EP 0674632 A JP 8504788 T MX 9307983 A	23-06-94 19-07-94 04-10-95 21-05-96 31-08-94